



# Micromedex

碩睿資訊有限公司  
教育訓練部門

# 大綱

Micromedex 內容簡介

Micromedex 使用介面

Micromedex Assistant

Micromedex 檢索運用範例





# Micromedex 內容簡介

# Micromedex 收錄內容範圍



藥物資訊



治療方式



藥物毒性



替代療法



病患衛教

Micromedex® Solutions Healthcare Series

# 內容特性



## 權威性

藥物、毒理、疾病與急診醫學內容受美國國務院採納為官方醫學百科




## 高品質

嚴謹的編輯過程



## 專業可靠

為學校、醫院及藥廠等提供實證內容服務超過50年



## 內容一致

呈現格式與內容標準皆維持一致



## 全文閱讀

內容皆具完整參考文獻、經由同儕評審，並由臨床醫師撰寫

# 資料來源與編輯方法



## 檢閱全球的醫療文獻

>15,000篇醫學文獻/週  
監控約 8,500 本期刊  
定期進行高階及深度檢閱



## 內部編輯團隊

擁有研究方法專業知識並  
受過臨床訓練的編輯專員

# 資料庫內容

Drug Information	Disease Information
<b>DRUGDEX<sup>®</sup> System</b> <b>DRUG-REAX<sup>®</sup> System</b> <b>MARTINDALE</b> <b>Index Nominum</b> <b>Physicians' Desk Reference<sup>®</sup>(PDR<sup>®</sup>)</b> <b>P &amp; T QUIK<sup>®</sup> Reports</b> <b>IV INDEX<sup>®</sup> System</b> <b>IDENTIDEX<sup>®</sup> System</b> <b>Red Book<sup>®</sup> Online</b>	<b>DISEASEDEX<sup>™</sup> General Medicine</b> <b>DISEASEDEX<sup>™</sup> Emergency Med.</b> <b>Lab adviser<sup>™</sup></b>
	<b>Patient Education</b>
	<b>AltCareDex<sup>®</sup> Alternative Medicine Education</b> <b>CareNotes<sup>™</sup> System</b>
	<b>Toxicology Information</b>
	<b>POISINDEX<sup>®</sup> System</b> <b>TOMES<sup>®</sup> System</b> <b>REPRORISK<sup>®</sup> System</b>
<b>Alternative Medicine</b>	<b>Free Resources</b>
<b>AltMedDex<sup>®</sup> System</b> <b>AltMedDex<sup>®</sup> Protocols</b>	<b>Calculators</b> <b>Micromedex App</b>



# Micromedex 使用

# 資料庫登入與使用



## IP認證機制

- 在IP範圍內，從單位圖書館網頁連結
- 校 / 院外連線：
  - 輸入帳密
  - 設定Proxy或VPN
- **完整全文內容**



## 行動載具APP 訂戶專屬


- 每次登入會自動更新資料
- **Drug Reference可離線使用**，不受網路死角影響
- 僅有簡要解答內容

\*更新資料時需有網路

# APP下載




Micromedex




可離線使用，不受制於使用人數

# APP 啟用方式 – 手機使用機構網域內 Wi-Fi

安裝開啟APP




在IP網域內  
登入啟用



下載更新資料




完成啟用



# APP 啟用方式 — 手機非使用機構網域內Wi-Fi

## (1) 複製code



## (2) 開啟網頁版Micromedex資料庫下載中心點擊啟用網址

Micromedex

Monograph search Q Keyword search

Feedback Mobile access User account Logout

Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes NeoFax® / Pediatrics Tox & Drug Product Lookup RED BOOK Calculators Formulary

Merative mobileMicromedex®  
Put the power of Micromedex on your mobile device

↓ Micromedex Mobile App Access (Included with subscription)

Micromedex Mobile App Access on Apple® and Android®

- The new Micromedex App for Apple and Android devices is included with your respective Merative Micromedex Drug content subscription.
- You can access this app via the App Store and Google Play®.
- You can activate the app by following the simple instructions below.

New Mobile App Activation and Instructions:

Step 1: Visit the App Store or Google Play® from your device and search Micromedex.

Step 2: From the App Store or Google Play, select download / install the application. You may be prompted to enter your Apple or Google ID.

Step 3: The app will download to your app library, or directly to your device.

Step 4: Open the app. The activation code will generate on the mobile device. Copy the code by tapping on a copy icon to the right of the code.

To activate the app:

- Tap on "Activate Now" button on your app. Enter login information if required.
- Follow the link to activate new mobile app via Micromedex online activation page.

OR

Step 5: Paste or enter the code in the "Activate Now" window on the mobile device or in the desktop application. Click "Activate Device". Begin using the app.

If you have issues with your login, please contact our support department:

Product Support:  
U.S. and Canada: 1.877.843.6796 for Product Technical Support [24x7]  
Global: +1.734.768.1510 for Product Technical Support [24x7]

Or file a case online via <https://merative.my.site.com/mysupport/s/micromedex-mobile-support-request>

Download on the App Store

GET IT ON Google Play

Micromedex Assistant

# APP 啟用方式 — 手機非使用機構網域內Wi-Fi

(3) 輸入code

Subscriber: Shou Ray Information Service Co Ltd.


**Activate Now**

TDHG-XKWF

Activate Device →


[Log out](#)

(4) 完成啟用



# APP首頁


更新、版本與設定






快速檢索

瀏覽工具方式



選擇使用工具




# APP首頁-Calcs




# APP 使用畫面-以 Drug Reference 為例



輸入欲查詢藥品名稱




從搜尋結果選擇藥品






點選查看各項說明

# APP 使用畫面-以 Drug Reference 為例

開啟選單




查看參考來源



開啟目錄

# APP 使用畫面-以 選單功能 為例

開啟選單





查看參考來源

References



[4] Product Information: COUMADIN(R) oral tablets, warfarin sodium oral tablets. Bristol-Myers Squibb Company (per manufacturer), Princeton, NJ, 2019.

Close




開啟目錄


# APP 使用畫面-以 選單功能 為例



Feedback




Bookmark




Find in Page



# APP-Micromedex Assistant



開啟 Micromedex Assistant



# APP-Voice Search



- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

- Do not crush drugs list
- Extravasation
- Drug classes
- Drug consults

Search drug, disease, toxicology and more


Q Drug name or keyword search

Micromedex Assistant

# 意見反饋

## Tell us about your experience

Reason for feedback

Choose an option 

- Content
- Technical
- Other

選擇反饋類型

Close

Submit

# APP 下載中心



Monograph search

Feedback

**Mobile access**

User account

Logout

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

## Merative mobile **Micromedex**®

Put the power of Micromedex on your mobile device

**按使用載具不同各有說明**

↓ **Micromedex Mobile App Access (Included with subscription)**

↓ **Micromedex Assistant for Mobile Browsers (Online Conversational Search, subscription required)**

↓ **Merative Micromedex Assistant (Remote online access to enterprise subscription)**

[Contact us](#) for any Comments/Suggestions to MICROMEDEX

[Micromedexsolutions.com](#) ^

[Support](#) ^

[Latest News](#)



© Merative US L.P. 1973, 2025



碩睿資訊有限公司

# 我的訂閱

## MY SUBSCRIPTION

用於 Shou Ray Information Service Co Ltd.

已經訂購

尚未訂購

### Subscribed

#### Micromedex applications

- ✓ AAPCC Codes in POISINDEX
- ✓ Alternative Medicine
- ✓ Detailed Drug Information for the Consumer
- ✓ DISEASEDEX™ Emergency Medicine
- ✓ DISEASEDEX™ General Medicine
- ✓ DRUGDEX System
- ✓ Imprint Codes in Identidex
- ✓ Index Nominum
- ✓ Interaction Checking
- ✓ IV Compatibility
- ✓ Lab Advisor
- ✓ MARTINDALE

### Not subscribed

#### Micromedex applications

- ⊗ AI in MDX- Beta
- ⊗ API CareNotes and DrugNotes
- ⊗ API In-Depth Drug
- ⊗ API Summary Drug
- ⊗ Micromedex AI-Powered Search
- ⊗ Micromedex Assistant for Mobile Browsers

My subscription

Gateway

列印

關閉

Micromedex Assistant

# 閘道

## My products

Micromedex →

CareNotes →


Formulary →

根據機構單位使用權限模組切換

[Log in with a different username](#)



[Log out](#)


# 常用資源

- Home 
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax<sup>®</sup> / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

- Do not crush drugs list
- Extravasation
- Drug classes
- Drug consults

Search drug, disease, toxicology and more

Micromedex Assistant 



# Do Not Crush Drug List

## Do Not Crush List

藥物諮詢

## 勿磨碎或咀嚼口服藥清單

列印

頁首

### RESPONSE

A variety of oral solid dosage forms should not be crushed or chewed prior to administration because of their formulation. In general, these include:

- a) Extended-release, a term used synonymously with controlled-release, prolonged-action, and sustained-release formulations
- b) Enteric or protective coated medications
- c) Medications formulated for sublingual or buccal absorption, or those designed to exert a local effect in the mouth (eg, lozenges)
- d) Medications that are offensive-tasting to the patient, irritate the oral mucosa, or contain dyes or substances that may stain the teeth or oral mucosa; these may be given to patients with nasogastric (NG) tubes
- e) Medications that are potentially hazardous, as described below, and require special handling to limit exposure to health risks
- f) Medications that are manufactured by a certain technology to discourage or deter misuse and abuse

Occupational exposure to hazardous drugs (eg, antineoplastics, antivirals, biological modifiers, hormones) poses a risk to health care workers including acute health effects like rashes, chronic effects including cancer, and adverse reproductive effects. The 2024 NIOSH List of Hazardous Drugs in Healthcare Settings is an alphabetical listing of drugs that meet the criteria as a hazardous drug (Table 1 and Table 2), and drugs with only a developmental and/or reproductive risk. For more specific information, see Drug Consult: NIOSH—Handling Hazardous Drugs in Healthcare Settings [1].

- Table 1: Drugs with MSHI in the package insert and/or meet the NIOSH definition of a hazardous drug and one or more of the following criteria: are classified by the National Toxicology Program (NTP) as "known to be a human carcinogen," or are classified by International Agency for Research on Cancer (IARC) as Group 1 "carcinogenic to humans" or Group 2A "probably carcinogenic to humans" [1].
- Table 2: Drugs that meet the NIOSH definition of a hazardous drug and do not have MSHI, are not classified by the NTP as "known to be a human carcinogen," and are not classified by IARC as Group 1 "carcinogenic to humans" or Group 2A "probably carcinogenic to humans" [1].

### Capsules/Tablets That Should Not Be Crushed List

This list serves as a general guide and is not all inclusive. Products are listed alphabetically by name (trade or generic).

Clinicians should use their best judgment based on an individual patient's medical need.

Unless otherwise specified, the source of the information is obtained from the manufacturer's prescribing information.

#### Capsules/Tablets That Should Not Be Crushed\*

Trade/Generic Drug Names	Dosage Form	Comments
abemaciclib	Tablet	
abiraterone acetate#	Tablet	
abiraterone acetate, micronized#	Tablet	
abrocitinib	Tablet	Swallow tablets whole with water; do not crush, split, or chew
acalabrutinib	Capsule; Tablet	

# Extravasation

## Extravasation

藥物諮詢

## 外滲或浸潤處理流程

列印

頁首

### PATIENT DATA/BACKGROUND

Drugs administered IV may leak into the surrounding tissue causing extravasation or infiltration. Extravasation is the leakage of vesicants that can cause blistering and tissue necrosis. Infiltration is the leakage of irritants that can cause inflammation and pain but not tissue necrosis [1][2]. Extravasation can result in severe injury with subsequent functional impairment and residual cosmetic defects [3][4].

Most cases of extravasation involve cytotoxic agents [2]. Cytotoxic agents that cause tissue injury may be classified into 3 types [5]:

- Vesicants - Agents that are capable of causing soft tissue damage by causing blistering and necrosis
- Irritants - Agents that cause inflammatory reactions
- Nonvesicants - Agents that do not produce necrosis or inflammation (defined from the European Oncology Nursing Society)

Serious cases associated with noncytotoxic agents that required surgical debridement and skin grafting, prolonged hospitalization, and increased morbidity have been reported [3][6][4]. The initial presentation often does not indicate the extent of tissue damage [3][7][4].

Extravasation of monoclonal antibodies has also been reported and has been managed successfully with general conservative interventions including aspiration of the extravasated solution, avoidance of manual pressure over the extravasated site, limb elevation, and removal of the cannula and has resulted in no sequelae [8].

Extravasation is a potential hazard of chemotherapy. The most common symptoms of extravasation include feelings of tingling, burning, discomfort or pain, and swelling and redness at the injection site. Symptoms of blistering, necrosis, and ulceration may occur later. Signs that might indicate extravasation are the absence of blood return, resistance on the plunger of the syringe during delivery of a bolus injection, or an interruption of the free flow of an infusion [9]. However, in some cases there is an absence of symptoms and extravasation may only appear after several days or weeks when the first signs of progressive tissue damage occurs [10]. The damage may range from localized, self-limiting inflammation (irritants) to full-thickness destruction and sloughing of the skin (vesicants) [11].

Extravasation in neonates and children presents a challenging clinical scenario due to their fine skin and thin subcutaneous fat. There is risk of extravasation due to their small vessels with fragile vessel walls, cannula fixation difficulty, prolonged IV therapy, and the limited ability of this population to communicate pain [12].

Information on risk factors, prevention, and management of extravasation is presented according to the following outline.

I. Risk Factors and Severity
II. Prevention
III. Nonpharmacologic Management
IV. Alphabetical Listing of Agents With Reported Extravasation and Any Specific Management

## 藥物發生外滲處置流程及預防


### RESPONSE

#### I. Risk Factors and Severity

Risk factors for extravasation include [5][2][9][3][7][4]:

- Agent-Related Factors:
  - cytotoxicity - DNA binding more likely than non-DNA binding
  - high osmolality

# Drug Classes



Monograph search  Keyword search

Feedback Mobile access User account Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## Drug Classes



跳轉到: [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

Displaying 184 of 761 results for "Drug Classes"

藥物類別

[ACE Inhibitor](#)

[ACE Inhibitor/Calcium Channel Blocker Combination](#)

[ACE Inhibitor/Thiazide Combination](#)

[Acetaminophen Antidote](#)

[Acetaminophen Combination](#)

[Acetic Acid \(class\)](#)

[Acid-Base Disorder Agent](#)

[Adamantane](#)

[Adenosine A2a Receptor Agonist](#)

[Adenosine Receptor Agonist](#)

[ADP-Induced Aggregation Inhibitor](#)

[Adrenal Glucocorticoid](#)

Micromedex Assistant

# Drug Consults



Monograph search  Keyword search

Feedback Mobile access User account Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## Drug Consults



跳轉到: [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) 0-9

顯示 51 of 650 藥物諮詢文章

藥物諮詢

### Abbreviations

ABFM (Augmented Berlin-Frankfurt-Muenster) +/- Nelarabine - Used for T-cell Acute Lymphoblastic Leukemia

Abuse-Deterrent Opioid Medications

治療霍奇金氏淋巴瘤的藥物

ABVD - Used for Hodgkin's Disease

AC - Used for Breast Cancer

AC FOLLOWED BY T WITH TRASTUZUMAB - Used for Breast Cancer

Accidental Awareness During General Anesthesia

ACE Inhibitor-Induced Acute Renal Failure

ACE Inhibitor-Induced Angioedema

ACE Inhibitor-Induced Cough

ACE Inhibitor-Induced Hepatotoxicity

ACE Inhibitor-Induced Hypotension

### ABVD - Used for Hodgkin's Disease

Drug Consults


#### RESPONSE

- DOXOrubicin 25 mg/m(2) IV, days 1 and 15
- Bleomycin 10 mg/m(2) IV, days 1 and 15
- VinBLAStine 6 mg/m(2) IV, days 1 and 15
- Dacarbazine 375 mg/m(2) IV, days 1 and 15 [1]
- Repeat cycle every 28 days

#### Reference

1. Bonadonna G & Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982; 9(1):21-35. PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>

Last Modified: February 06, 2017



Micromedex Assistant

# 引用 Micromedex

## HOW TO REFERENCE THE Merative SYSTEMS

[Top of page](#)

PLEASE NOTE: When referencing a Micromedex product or database, you *must* include: (electronic version), Merative information, URL address (<https://www.micromedexsolutions.com/>) and the date accessed.

Subscribers to the Licensed Solutions often ask how to reference the databases when publishing articles. The following formats should be used:

### The entire Micromedex System:

[Top of page](#)

Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

### An entire System or Database:

[Top of page](#)

#### Merative™ Micromedex® Alternative Medicine:

Merative™ Micromedex® Alternative Medicine (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

#### CareNotes®:

CareNotes® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

#### Merative™ Micromedex® Disease Emergency Medicine:

Merative™ Micromedex® Disease - Emergency Medicine (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

#### Merative™ Micromedex® Disease General Medicine:

Merative™ Micromedex® Disease - General Medicine (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

#### Dosing & Therapeutic Tools Database:

Dosing & Therapeutic Tools Database (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

#### Merative™ Micromedex® DRUGDEX®:


Merative™ Micromedex® DRUGDEX® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

#### Merative™ Micromedex® Drug Interaction Checking:










Merative™ Micromedex® Drug Interaction Checking (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).

#### MARTINDALE:

Sweetman S (Ed), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Electronic version, Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: *month/day/year*).



# 操作使用說明手冊



-  Overview
-  Home Page
-  Micromedex Assistant
-  Searching
-  Content
-  Tools
-  Micromedex on Your Mobile Device
-  Other Applications
-  Browser Settings


## Micromedex® Home Page

### Searches Made Simple

With the prominently displayed *Keyword* search box that is available on every page in Micromedex® you have direct access to the information you need. It also provides intelligent searching with in-line spelling suggestions.

Search drug, disease, toxicology and more

Micromedex Assistant 

Help

Training Center

Compendia resources

## Micromedex Training Center



依身份需求不同進行學習

View resources by role



### For Nurses

Be prepared for any patient you encounter with evidence-based content, drug interaction checker, calculators and other tools.

[Explore resources for Nurses](#)



### For Pharmacists

Get fast access to current drug information to resolve complex drug therapy issues and support patient safety.

[Explore resources for Pharmacists](#)




### For Physicians


Stay current on the latest drug and disease evidence with daily, reliable clinical updates.

[Explore resources for Physicians](#)

- Help
- Training Center
- Compendia resources



# 最新消息 Latest News

Home 

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

## Latest News

New/Expanded Indications Oct/Nov 


New Drug Approvals Oct/Nov 

Content Update Highlights 

Have you seen AI-powered search yet? 

Patient Education (CareNotes) Content Update Highlights: October 2025 

Close

Micromedex Assistant 



# Micromedex Assistant 有問題，MA 來幫你！

# Micromedex 為何需要MA?



資料太多眼昏花

# Micromedex 為何需要MA?



**Micromedex  
Assistant**



**MA相助精準查**

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

Search drug, disease, toxicology and more

Micromedex Assistant



# 怎麼問MA?

像同事之間一樣問問題

MA現在知道:

**藥物資訊**

藥物分類、劑量、給藥、藥物安全性、作用、藥物動力學、關於機制

**藥物交互作用**

**IV相容性**

Solution, Y site, Admixture, Syringe, TPN / TNA

MA不知道:

NeoFax / Pediatrics, Toxicology, Disease, Lab, Alternative Medicine, Reproductive Risk  
第三方內容 (例如Martindale, Index Nominum)

## About Micromedex Assistant

### Conversational Search:

Micromedex Assistant uses cognitive computing in the IBM cloud to gather search intent through conversation, provide specific clinical answers, and guide clinicians to relevant evidence.

### How Micromedex Assistant Works:

Ask questions in a natural way, the way clinicians ask clinicians. The more specific the question, the more specific the answer. Examples:

- What's the adult dose of lisinopril for hypertension?
- What are approved uses for pristin? (Note: pristin is misspelled in the image)
- What are the adverse effects of digoxin?
- Can cefazolin be given IV push?
- How fast can Daptomycin be given?

### Micromedex Assistant Understands:

Micromedex Assistant is in medical residency and can answer many drug information questions. The system learns from interaction with users and will be able to answer more sophisticated questions over time. For now, answers are limited to:

- Drug Information (e.g. Drug Classes, Dosing, Administration, Medication Safety, Mechanism of Action, Pharmacokinetics, About)
- Drug Interactions
- IV Compatibility

### Micromedex Assistant does NOT Understand:

關閉 X

# Demo Slides

## 對話式檢索範例

就像跟你的同事問問題一樣，  
對話將提供簡要解答內容、簡要解答連結、深入解答連結

- Dosing and adjustments 劑量與調整
- Adverse effects 不良反應
- Contraindications 禁忌症
- Precautions 注意事項
- Administration 管理
- More 更多

提問範例：

“What’s the adult dose of warfarin for Atrial fibrillation?”

The screenshot shows the Micromedex Assistant interface. At the top, there are search filters: "Warfarin So...", "Atrial fibrillati...", and "adult". A "Clear" button is on the right. Below the filters, a search bar contains the query: "What's the adult dose of warfarin for Atrial fibrillation". The main content area displays the following information:

Here is the adult dosing for warfarin sodium:

**Atrial fibrillation - Thromboembolic disorder**

- Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day (FDA dosage)
- Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus (FDA dosage).
- Following an ischemic stroke or TIA, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosage)

**Atrial fibrillation - Thromboembolic disorder; Prophylaxis**

- Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day
- Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus.

Quick Answers Adult Dosing for Warfarin Sodium

Was this helpful?

Type something...

# 對話式檢索介面

## 智能過濾器

Warfarin ... x Atrial fibr... x adult x Clear

Here is the adult dosing for warfarin sodium:

### Atrial fibrillation - Thromboembolic disorder



- Initial, 2 to 5 mg orally once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg orally once a day
- Following an ischemic stroke or transient ischemic attack, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosing)

### Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on INR; usual maintenance, 2 to 10 mg orally once a day

Quick Answers Adult Dosing for Warfarin Sodium

In-Depth Answers Adult Dosing for Warfarin Sodium

Was this helpful?  

Type something...


## 簡要解答內容

## 簡要解答連結

## 深入解答連結

## 意見回饋

## 對話檢索框



Micromedex Assistant

Warfarin So... x Atrial fibrillati... x adult x Clear

What's the adult dose of warfarin for Atrial fibrillation

Here is the adult dosing for warfarin sodium:



### Atrial fibrillation - Thromboembolic disorder

- Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day (FDA dosage)
- Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus (FDA dosage)
- Following an ischemic stroke or TIA, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosage)

### Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day
- Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus

Quick Answers Adult Dosing for Warfarin Sodium

Was this helpful?  

Type something...

## 對話式檢索範例

無論是手滑打錯、語意不明、病名縮寫都沒關係，MA會再次確認，提供你正確答案

提問範例：  
adult warfarin AF

Which of the following subjects would you like to see?

Dosing

The screenshot shows the Micromedex Assistant interface. At the top, there are search tabs for 'Warfarin So...', 'Atrial fibrillati...', and 'adult', with a 'Clear' button. A search input field contains 'adult warfarin AF'. Below the search bar, a list of subjects is displayed: 'Adverse Effects', 'Precautions', 'Contraindications', 'Uses', and 'Dosing'. The 'Dosing' option is selected, and a 'Dosing' button is visible. The main content area displays the following text: 'Here is the adult dosing for warfarin sodium: Atrial fibrillation - Thromboembolic disorder'. Below this, there are three bullet points detailing the dosing regimen: 'Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day (FDA dosage)', 'Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus (FDA dosage)', and 'Following an ischemic stroke or TIA, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosage)'. At the bottom, there is a 'Type something...' input field and a 'Was this helpful?' feedback button.

## 對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：

Are dose adjustment needed?

The screenshot shows the Micromedex Assistant interface. At the top, there are search filters: 'Warfarin So...', 'Atrial fibrillati...', and 'adult'. A 'Clear' button is on the right. Below the filters, a teal button reads 'In-Depth Answers Adult Dosing for Warfarin Sodium'. A dark grey speech bubble contains the question 'Are dose adjustment needed'. Below this, the text reads 'Here are the warfarin sodium dose adjustments:'. A bulleted list follows, detailing adjustments for renal impairment, geriatric patients, Asian patients, INR values, bariatric surgery, discontinuing therapy, postpartum, and pregnancy. At the bottom, there are two teal buttons: 'Quick Answers Warfarin Sodium Dose Adjustments' and 'In-Depth Answers Warfarin Sodium Dose Adjustments'. A 'Was this helpful?' prompt with thumbs up/down icons is visible. At the very bottom, there is a text input field with the placeholder 'Type something...'.

## 對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：

What patient monitoring is needed?

The screenshot shows the Micromedex Assistant interface. At the top, there are search filters: "Warfarin So...", "Atrial fibrillati...", and "adult". A "Clear" button is on the right. Below the filters, a search bar contains the question "What patient monitoring is needed?". The main content area displays the following information:

Here is the warfarin sodium monitoring information:

- INR: daily following the initial dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks; additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly; patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer)
- INR: up to every 12 weeks in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing; evaluate INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines)
- INR: Immediately prior to any dental or surgical procedure
- INR (pediatric): More frequently to ensure target INR is achieved and maintained the low-dose prophylactic target INR is 1.7 (range 1.5 to 1.9)
- INR: More frequently in patients with high risk of bleeding, when starting or stopping other drugs, changing dosages of other drugs, and in patients with renal impairment
- INR (when administered with heparin): Sample at least 5 hours after the last IV bolus dose of heparin, 4 hours after stopping continuous IV heparin infusion, 24 hours after the last subcutaneous heparin injection
- Target INR: 2.5 (range, 2 to 3) in adults and pediatric patients in most indications
- Target INR: 3 (range 2.5 to 3.5) mechanical mitral valve, mechanical heart valves in both the aortic and mitral position, those undergoing percutaneous mitral balloon valvotomy with preprocedural transesophageal echocardiogram who demonstrate a left atrial thrombus, caged ball or caged disk valves , caged ball or caged disk valves
- Pregnancy test: Prior to initiation in female patients of reproductive potential
- Signs or symptoms of bleeding: Regularly during therapy, with more frequent monitoring in those with increased risk (high intensity of anticoagulation (INR greater than 4.0), age 65 years or older, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, anemia, malignancy, trauma, renal impairment, VKORC1 and CYP2C9 gene variants, concomitant use of drugs with increased bleeding risk and long duration of therapy)

At the bottom right of the content area, there is a "Was this helpful?" prompt with thumbs up and thumbs down icons. Below the content area is a text input field labeled "Type something..."

## 對話式檢索範例

如在前述問題下接續詢問前述藥物與特定藥物的交互作用，結果將提供連結引導您到藥物交互作用的頁面

提問範例：

Are there interactions with TAMOXIFEN?

Here are the drug interactions for tamoxifen citrate:

[View Drug Interactions Results](#)

The screenshot shows the Micromedex Assistant interface. At the top, there are search filters for 'Tamoxifen C...', 'Atrial fibrillati...', and 'adult'. Below this, the 'Drug Interaction Results' section is displayed. It includes a '修改相互作用' (Modify Interaction) button, a '細化方式' (Refinement Method) dropdown set to 'Drug Tamoxifen Citrate', a '嚴重性' (Severity) dropdown set to 'All', and a '文件' (File) dropdown set to 'All'. A navigation bar shows links to 'Drug-Drug (111)', '過敏症狀 (0)', '食物 (0)', '乙醇 (0)', '實驗室 (0)', '抽煙 (0)', '懷孕 (1)', and '哺乳期 (1)'. The main content area is titled 'Drug-Drug 相互作用 (111)' and contains a table of drug interactions.

藥物：	嚴重性：	文件：
MESORIDAZINE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Excellent
WARFARIN [Systemic] -- TAMOXIFEN [Systemic]	Contraindicated	Good
ZIPRASIDONE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair
SAQUINAVIR -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair

Below the table, a chat interface is visible. It contains the question 'Are there interactions with TAMOXIFEN?', the answer 'Here are the drug interactions for tamoxifen citrate:', and a button 'View Drug Interactions Results'. At the bottom of the chat, there is a 'Was this helpful?' feedback prompt and a text input field with the placeholder '[Type something...]'.

# 對話式檢索範例

除單一藥物的交互作用清單外，亦可直接查詢多個藥物交互作用

提問範例：  
interactions among bilberry  
Losartan Warfarin ibuprofen?

I've found multiple results for drug.  
Which one are you looking for?

- Ibuprofen
- Ibuprofen Lysine

Ibuprofen

Here are the drug interactions for ibuprofen, losartan potassium and warfarin sodium:

[View Drug Interactions Results](#)

**Micromedex Assistant**

Drug Interaction Results

優化方式: 劑型: All 嚴重性: All 文件: All 類型: All

篩選到: 藥物-藥物 (2) | 複方 (0) | 過敏症狀 (0) | 食物 (13) | 乙醇 (1) | 實驗室 (1) | 抽屜 (1) | 懷孕 (3) | 哺乳期 (3)

藥物:	嚴重性:	文件:	描述:
IBUPROFEN -- WARFARIN SODIUM	Major	Fair	Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.
IBUPROFEN -- LOSARTAN POTASSIUM	Moderate	Excellent	Concurrent use of ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS and NSAIDS may result in renal dysfunction and/or increased blood pressure.

複方 (未找到)

Drug-過敏症狀 相互作用 (未找到)

藥物:	嚴重性:	文件:	描述:
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.

interactions among bilberry Losartan Warfarin ibuprofen?

I've found multiple results for drug. Which one are you looking for?

- Ibuprofen
- Ibuprofen Lysine

Ibuprofen

Here are the drug interactions for ibuprofen, losartan potassium and warfarin sodium:

[View Drug Interactions Results](#)

Was this helpful?

Type something...



# 檢索與工具運用案例

# 案例參考

- 病人

一位75歲女性有心房顫動合併高血壓的病人，為高中風風險族群，過去曾使用Aspirin預防中風，但因腸胃道不適而停藥

- 家屬關心

擔心使用抗凝血藥物預防中風，是否會增加出血風險？

- 醫生考慮

應該使用抗凝血藥物預防中風嗎？如必須使用該如何調整？




# 利用Micromedex尋求支持的證據

Search drug, disease, toxicology and more

Q aspiri  

- Aspiricor
- Aspirin
- Dosing Aspirin
- Adverse Effects Aspirin
- Indications Aspirin
- Interactions Aspirin
- Aspirin (Buffered)

Micromedex Assistant 

# Aspirin- Non-FDA Uses

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## Aspirin

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

Regulatory Authority

FDA

簡要解答

深入解答

全部結果

一次載入所有內容，以便快速跳轉

### Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA Uses
- Non-FDA Uses**
- Administration
- Comparative Efficacy
- Place In Therapy

### Dosing/Administration

#### Non-FDA Uses

請參閱 '簡要解答' 瞭解綜述結果。

Expand All

Expand All to view the entire section.

Angina pectoris

Antiphospholipid syndrome

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

Cancer - Thromboembolic disorder; Prophylaxis

Carotid artery stenosis, Asymptomatic or symptomatic

檢視完整文件

列印

### 相關結果

- 替代藥物
- 毒理學
- 疾病

- Drug Consults
- Index Nominum
- Martindale
- Product Lookup - Martindale
- Product Lookup - RED Book
- Product Lookup - Tox & Drug
- 消費者藥物資訊

Micromedex Assistant

# Aspirin- Comparative Efficacy

## 1. 考量問題：是否有其他藥物可選擇？

### ASPIRIN

Drug Classes: Analgesic | Antipyretic | All

Routes: Oral | Rectal

Regulatory Authority

簡要解答

深入解答

全部結果

Atrial fibrillation - Thromboembolism -- Comparative Efficacy

1 / 2 results 用於 atrial fibrillation - thromboembolic disorder; ...

every 12 hours of enoxaparin sodium 20 mg (n=55) daily in addition to low-dose aspirin. The rate of primary events between the heparin and enoxaparin groups was similar. There appears to be a

#### Atrial fibrillation - Thromboembolic disorder; Prophylaxis

##### 1) Overview

FDA Approval: Adult, no; Pediatric, no

Efficacy: Adult, Evidence is inconclusive

Recommendation: Adult, Class III

Strength of Evidence: Adult, Category B

See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

##### 2) Summary:

###### Evidence

- An observational study in patients taking oral anticoagulation alone
- Aspirin and aspirin plus mini-d

2 / 2 results 用於 atrial fibrillation - thromboembolic disorder; ...

respectively (p less than 0.0001 versus warfarin). Withdrawals due to adverse effects were statistically similar (4% and 3% in the warfarin and aspirin groups, respectively). Prior stroke and abnormal LV ejection fraction were significant prognostic risk factors for the development of stroke [897].

#### Atrial fibrillation - Thromboembolic disorder; Prophylaxis

a) The second Stroke Prevention in Atrial Fibrillation (SPAF-II) study demonstrated an increase in stroke rate in older compared to younger patients regardless of warfarin or aspirin therapy for non-rheumatic atrial fibrillation. Patients received dose-adjusted warfarin (INR 2.0 to 4.5) or aspirin 325 mg daily. Primary events were defined as ischemic stroke and systemic embolism. In patients 75 years or less (n=715) the rate of primary events in the aspirin group were 1.9% per year compared to 1.3% in the warfarin group (p=0.24). In patients older than 75 years (n=385) the rate of primary events in the aspirin group were 4.8% per year compared to 3.6% per year in the warfarin group (p=0.39). Patients (older than 75) in both the warfarin and aspirin group had similar stroke rates per year with residual deficit (hemorrhagic and ischemic), 4.6% and 4.3% respectively. With regard to all patients (ages combined), annual primary events were lower in the warfarin versus aspirin-treated group (1.9% and 2.7%, respectively; p=0.15). Selecting safe antithrombotic therapy for atrial fibrillation in older patients remains a challenge [90].

b) Warfarin was superior to aspirin in preventing thromboembolic complications and vascular deaths in chronic, non-rheumatic atrial fibrillation in a controlled study involving 1007 outpatients. In this study, warfarin was given in an open fashion, with the aspirin and placebo arms being double-blind. Warfarin was given in doses to achieve a therapeutic range of 4.2 to 2.8 INR (international normalized ratio); aspirin was given as 75 mg once daily. Anticoagulation with warfarin should be considered in patients with chronic atrial fibrillation as long as contraindications are not present. In a follow-up report of the subjects in this study who received placebo, thromboembolic complications occurred significantly more frequently in those that had a previous myocardial infarction [898][899].

c) BAATAF (Boston Area Anticoagulation Trial for Atrial Fibrillation) Study: Warfarin was superior to aspirin for prevention of stroke in patients with nonrheumatic atrial fibrillation. In this study, the annual rate of stroke occurrence was 0.45% among warfarin users compared to 3.9% among aspirin users and 1.8% among untreated patients. After controlling for various risk factors, the relative stroke rate with warfarin over that of aspirin was 0.135 (95% CI 0.029 to 0.64). The relative stroke rate of warfarin over that of untreated patients was also low, however, the 95% CI was extremely wide and included unity, probably as a result of insufficient power of the study [900].

b) 在一項 1,007 名門診患者的對照研究中，Warfarin 在預防慢性非風濕性心房顫動的血栓栓塞併發症和血管死亡方面優於 Aspirin。... 只要不存在禁忌症，慢性心房顫動患者應考慮使用 Warfarin 進行抗凝治療。

c) BAATAF (波士頓地區房顫抗凝試驗) 研究：**Warfarin 在預防非風濕性心房顫動患者中風方面優於 Aspirin**。在這項研究中，Warfarin 使用者的年中風發生率為 0.45%，而 Aspirin 使用者為 3.9%，未經治療的患者為 1.8%

# Warfarin- FDA Uses

## 2. 考量問題：此藥物的適應症為何？

Micromedex

Monograph search

Feedback Mobile access User account Logout

Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes NeoFax® / Pediatrics Tox & Drug Product Lookup RED BOOK Calculators Formulary

### Warfarin [您的的搜尋： Warfarin]

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: **Oral**

Regulatory Authority:

簡要解答 深入解答 全部結果

#### Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA Uses**
- Non-FDA Uses
- Administration
- Comparative Efficacy
- Place In Therapy

#### Medication Safety

- Contraindications
- Precautions

#### Dosing/Administration

##### FDA Uses

請參閱 '簡要解答' 瞭解綜述結果。

Expand All Expand All to view the entire section.

##### Warfarin Sodium

- Anticoagulant therapy, Genotype-guided
- Atrial fibrillation - Thromboembolic disorder; Treatment and Prophylaxis**

FDA Labeled Indication  
a) Overview

檢視完整文件  
 列印

#### 相關結果

- 替代藥物
- 毒理學
- 疾病

- Drug Consults
- Index Nominum
- Martindale
- Product Lookup - Martindale
- Product Lookup - RED Book
- Product Lookup - Tox & Drug
- 消費者藥物資訊

# FDA Uses

Expand All ← Expand All to view the entire section.

**Warfarin Sodium**

**Anticoagulant therapy, Genotype-guided**

**Atrial fibrillation - Thromboembolic disorder; Treatment and Prophylaxis**


FDA Labeled Indication  
 a) Overview  
 FDA Approval: Adult, yes; Pediatric, no  
 Efficacy: Adult, Effective  
 Recommendation: Adult, Class IIb  
 Strength of Evidence: Adult, Category A  
 See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

- b) Summary:
- Product Availability
    - The marketing and distribution of warfarin sodium for injection has been discontinued as of 5/2/2014 [18]
  - Indication
    - Warfarin is indicated for the prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation [17].
  - Limitations of Use
    - Warfarin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the

是否為核准的適應症用藥？  
 有建議強度與證據等級嗎？

# 檢視證據等級與建議強度

## Recommendation, Evidence and Efficacy Ratings

藥物諮詢 

### RESPONSE

The Micromedex Efficacy, Strength of Evidence and Strength of Recommendation definitions are outlined below:

Class	Recommendation	Description
Class I	Recommended	The given test or treatment has been proven to be useful, and should be performed or administered.
Class IIa	Recommended, In Most Cases	The given test, or treatment is generally considered to be useful, and is indicated in most cases.
Class IIb	Recommended, In Some Cases	The given test, or treatment may be useful, and is indicated in some, but not most, cases.
Class III	Not Recommended	The given test, or treatment is not useful, and should be avoided.
Class Indeterminate	Evidence Inconclusive	

Category A	Category A evidence is based on data derived from: Meta-analyses of randomized controlled trials with homogeneity with regard to the directions and degrees of results between individual studies. Multiple, well-done randomized clinical trials involving large numbers of patients.
Category B	Category B evidence is based on data derived from: Meta-analyses of randomized controlled trials with conflicting conclusions with regard to the directions and degrees of results between individual studies. Randomized controlled trials that involved small numbers of patients or had significant methodological flaws (e.g., bias, drop-out rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-control studies, observational studies).
Category C	Category C evidence is based on data derived from: Expert opinion or consensus, case reports or case series.
No Evidence	

Class I	Effective	Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is effective
Class IIa	Evidence Favors Efficacy	Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but the weight of evidence and/or expert opinion favors efficacy.
Class IIb	Evidence is Inconclusive	Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but the weight of evidence and/or expert opinion argues against efficacy.
Class III	Ineffective	Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is ineffective.

# Therapeutic Uses

## 3. 考量問題：使用抗凝血藥物是否可顯著降低中風危險？

### Atrial fibrillation - Thromboembolic disorder; Treatment and Prophylaxis

FDA Labeled Indication

#### a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class IIb

Strength of Evidence: Adult, Category A

See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

#### 4) Older Adults

a) Adjusted-dose warfarin reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and other clinically significant arterial embolism compared with aspirin 75 mg/day, among patients 75 years or older with chronic atrial fibrillation or atrial flutter, with no significant difference on major extracranial hemorrhage (BAFTA; N=973) [25].

### 心房顫動的老年人預防血栓療效

a) 對於 75 歲或以上的慢性心房顫動或心房撲動患者，調整劑量的華法林與每天 75 毫克的阿斯匹靈相比，降低了致命性和非致命性致殘性中風（缺血性或出血性）、顱內出血和其他臨床上顯著的動脈栓塞的複合終點的發生率，但對主要顱外出血無顯著差異。

# 檢視資訊來源

## Atrial fibrillation - Thromboembolic disorder; Prophylaxis

a) Guidelines from The American College of Chest Physicians (ACCP) recommends long-term aspirin 75 to 325 mg orally per day in patients with a low risk of stroke (CHADS(2) score of 0) if they choose to receive antithrombotic therapy, and in intermediate to high risk patients (CHADS(2) score of 1 or 2) who are unsuitable for oral anticoagulant therapy or who choose not to receive anticoagulants [53].

原始文獻  
出處

53. You JJ, Singer DE, Howard PA, et al: Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 suppl):e531S-e575S.

[PubMed Abstract: http://www.ncbi.nlm.nih.gov/...](http://www.ncbi.nlm.nih.gov/...)

# Adverse Reactions

## 4. 考量問題：使用抗凝血藥物可能的不良反應？

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax® / Pediatrics	Tox & Drug Product Lookup	RED BOOK	Calculators	Formulary
------	-------------------	------------------	---------	-----------------	-----------	----------------------	---------------------------	----------	-------------	-----------

**Warfarin** [您的搜尋： Warfarin]

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: **Oral**

[簡要解答](#)
[深入解答](#)
[全部結果](#)

### Medication Safety

- Contraindications
- Precautions
- Adverse Effects**
- Boxed Warning
- REMS
- Drug Interactions (single)
- IV Compatibility (single)
- Pregnancy & Lactation
- Monitoring
- Do Not Confuse

### Mechanism of Action

Mechanism of Action

### Pharmacokinetics

Pharmacokinetics

### Patient Education

Medication Counseling

Patient Handouts

### Toxicology

### Medication Safety

#### Adverse Effects

請參閱 '簡要解答' 瞭解綜述結果。

Expand All

← Expand All to view the entire section.

Cardiovascular Effects

Dermatologic Effects

Endocrine/Metabolic Effects

Gastrointestinal Effects

Hematologic Effects

**Hepatic Effects**

Immunologic Effects

#### Hematologic Effects

##### Warfarin Sodium

- Anemia
- Blood coagulation disorder
- Eosinophil count raised
- Hemolytic anemia
- Hemorrhage
- Summary

檢視完整文件

列印

### 相關結果

[替代藥物](#)  
[毒理學](#)  
[疾病](#)

[Drug Consults](#)  
[Index Nominum](#)  
[Martindale](#)  
[Product Lookup - Martindale](#)  
[Product Lookup - RED Book](#)  
[Product Lookup - Tox & Drug](#)  
[消費者藥物資訊](#)

# Adverse Reactions

## Hemorrhage

### 出血的危險因子

#### c) Summary

**1) Risk factors** for major or fatal bleeding in patients taking warfarin sodium include a higher starting INR, age 65 years or older, variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs, and long duration of warfarin therapy [107]. Other risk factors for a major bleed occurring during warfarin anticoagulation are comorbid conditions, atrial fibrillation, and the first 90 days of warfarin therapy [117][118][119]. Regular monitoring of INR should be performed on all patients. More frequent monitoring, careful dose adjustment, and a shorter duration of therapy may be warranted in patients at high risk for bleeding [107].

#### Summary

##### a) General Information

- 1) Bleeding is one of the most common and potentially serious adverse effects with treatment. May cause significant and potentially fatal bleeding [107]
- 2) Increased risk with high-intensity anticoagulation (ie, INR greater than 4), age of 65 years or older, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors, concomitant use of drugs that affect hemostasis (eg, NSAIDs, other anticoagulants, antiplatelet agents, SSRIs), and long-term therapy [107]

##### b) Prevention and Management

- 1) Perform regular (ie, generally every 1 to 4 weeks) INR monitoring in all treated patients [107]
- 2) Consider more frequent INR monitoring, careful dose titration to desired INR, and shortest possible therapy duration in high-risk patients [107]
- 3) Monitor INR more frequently with treatment initiation, dose adjustment, or withdrawal of other drugs (including botanicals) [107]
- 4) Determine INR immediately before any dental or surgical procedure [107]
- 5) Adjust the dose to maintain INR on the low end of the therapeutic range to continue anticoagulation in patients undergoing minimally invasive procedures [107]
- 6) Do not routinely base vitamin K antagonist (ie, warfarin) therapy interruption solely on clinical prediction rules for bleeding [83].
- 7) If the timeline for anticoagulant reversal is more than 24 hours, interrupt therapy. Oral or parenteral vitamin K may be administered if necessary [107] based on INR [142].
- 8) If expedited (ie, within 1 to 24 hours) anticoagulant reversal is needed, withhold drug. Oral or parenteral vitamin K(1) may be administered if necessary [107]
- 9) If emergent (ie, within less than 1 hour) anticoagulant reversal is required, withhold drug. Consider high-dose phytonadione IV. Consider clotting factor supplementation with prothrombin complex concentrates (eg, 4-factor prothrombin complex concentrate, recombinant factor VIIA plus 3-factor prothrombin complex concentrate, activated prothrombin complex concentrate, 3-factor prothrombin complex concentrate, recombinant factor VIIA, or fresh frozen plasma) [107][142]
- 10) The following are evidence-based guidelines from the American College of Chest Physicians for managing elevated INR or bleeding in patients on vitamin K antagonist (ie, warfarin) therapy:
  - a) **INR between 4.5 and 10** with no evidence of bleeding:
    - 1) Routine use of vitamin K is not recommended [83].
  - b) INR greater than 10 with no evidence of bleeding:
    - 1) Administer oral vitamin K [83].
  - c) Vitamin K antagonist-associated major bleeding:
    - 1) Instead of plasma use, achieve rapid anticoagulation reversal with 4-factor prothrombin complex concentrate. Coadminister with vitamin K 5 to 10 mg via slow IV injection rather than attempting reversal with coagulation factor alone [83].

預防與管理：  
針對不良反應之處理建議

# Monitoring

## 5. 考量問題：使用抗凝血藥物須監測的項目/頻率？

Warfarin [您的搜尋： Warfarin]

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: **Oral**

簡要解答

深入解答

全部結果

### Medication Safety

[Contraindications](#)

[Precautions](#)

[Adverse Effects](#)

[Boxed Warning](#)

[REMS](#)

[Drug Interactions \(single\)](#)

[IV Compatibility \(single\)](#)

[Pregnancy & Lactation](#)

**Monitoring**

達到穩定狀態後的  
建議監測頻率

[Pharmacokinetics](#)

[Pharmacokinetics](#)

[Patient Education](#)

[Medication Counseling](#)

[Patient Handouts](#)

[Toxicology](#)

[Clinical Effects](#)

### Medication Safety

#### Monitoring

請參閱 ['簡要解答'](#) 瞭解綜述結果。

#### A) Warfarin Sodium

##### 1) Therapeutic

##### a) Laboratory Parameters

##### 1) INR

**a) Monitor INR daily** following the initial warfarin dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks. Perform additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly. patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer) [109].

**b) Monitor INR up to every 12 weeks** in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing. Evaluate the INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines) [83]

In general, the recommended target INR is 2.5 (range, 2 to 3) in adults and pediatric patients in most indications [91][83], except in the following situations:

Target INR is 3 (range 2.5 to 3.5):

mechanical mitral valve [81]mechanical heart valves in both the aortic and mitral position [81]those undergoing percutaneous mitral balloon valvotomy with preprocedural transesophageal echocardiogram who demonstrate a left atrial thrombus [81]caged ball or caged disk valves [109]

**c) Evaluate the INR immediately** prior to any dental or surgical procedure [109]

**d) Monitor INR more frequently** in pediatric patients to ensure target INR is achieved and maintained [109] In pediatric patients, the low-dose prophylactic target INR is 1.7 (range 1.5 to 1.9) [91].

##### 1) Coadministration with Heparin

**a) Heparin may affect INR, monitor INR at least** [109]:

5 hours after the last IV bolus dose of heparin4 hours after stopping continuous IV heparin infusion24 hours after the last subcutaneous heparin injection

檢視完整文件

列印

監測項目與  
監測頻率

### 相關結果

[替代藥物](#)

[毒理學](#)

[疾病](#)

[Drug Consults](#)

[Index Nominum](#)

[Martindale](#)

[Product Lookup - Martindale](#)

[Product Lookup - RED Book](#)

[Product Lookup - Tox & Drug](#)

[消費者藥物資訊](#)

# Patient Handouts

## 6. 考量問題：如何進行用藥指導？

Monitoring

Do Not Confuse

Mechanism of Action

Mechanism of Action

Pharmacokinetics

Pharmacokinetics

Patient Education

Medication Counseling

Patient Handouts

Toxicology

Clinical Effects

Range of Toxicity

Treatment

About

How Supplied

Drug Properties

Storage & Stability

Trade Names

Regulatory Status

References

### A) Warfarin (By mouth)

Warfarin

Prevents and treats blood clots. May lower the risk of serious complications after a heart attack. This medicine is a blood thinner.

When This Medicine Should Not Be Used:

This medicine is not right for everyone. Do not use it if you had an allergic reaction to warfarin, if you are pregnant, or if you have health problems that could cause bleeding.

How to Use This Medicine:

Tablet

Take your medicine as directed. Your dose may need to be changed several times to find what works best for you.

This medicine should come with a Medication Guide. Ask your pharmacist for a copy if you do not have one.

Missed dose: Take a dose as soon as you remember. If it is almost time for your next dose, wait until then and take a regular dose. Do not take extra medicine to make up for a missed dose.

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.

Drugs and Foods to Avoid:

Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products.

Many medicines and foods can affect how warfarin works and may affect the PT/INR test results. Tell your doctor before you start or stop any medicine, especially the following:

Co-enzyme Q10, echinacea, garlic, ginkgo, ginseng, goldenseal, or St John's wort

Another blood thinner, including apixaban, argatroban, bivalirudin, cilostazol, clopidogrel, dabigatran, desirudin, dipyridamole, heparin, lepirudin, prasugrel, rivaroxaban, ticlopidine

Medicine to treat depression or anxiety, including citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone

Medicine to treat an infection

NSAID pain or arthritis medicine, including aspirin, celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac. Check labels for over-the-counter medicines to find out if they contain an NSAID.

Steroid medicine, including dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone

Warfarin works best if you eat about the same amount of vitamin K every day. Foods high in vitamin K include asparagus, broccoli, brussels sprouts, cabbage, green leafy vegetables, plums, rhubarb, and canola oil. Talk to your doctor before you make changes to your normal diet.

Do not eat grapefruit or drink grapefruit juice while you are using this medicine.

Warnings While Using This Medicine:

It is not safe to take this medicine during pregnancy. It could harm an unborn baby. Tell your doctor right away if you become pregnant. Use an effective form of birth control to keep from getting pregnant during treatment and for at least 1 month after your last dose.



# 查找疾病資訊

輸入症狀或疾病名

# 查找疾病

Home 

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

Search drug, disease, toxicology and more

Heart f

Heart failure

Drugs that treat Heart failure


Drugs that cause Heart failure

Heart failure following cardiac surgery

Heart failure with normal ejection fraction

Drugs that treat Heart failure with normal ejection fraction

Heart failure with preserved ejection fraction

Micromedex Assistant 

# 查找疾病

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax® / Pediatrics	Tox & Drug Product Lookup	RED BOOK	Calculators	Formulary
------	-------------------	------------------	---------	-----------------	-----------	----------------------	---------------------------	----------	-------------	-----------

## 3869 找到以下項的結果： "Heart failure"

全部結果

### 篩選依據

- 藥物 (2218)
- 毒理學 (981)
- 疾病 (295)
- 實驗室 (20)
- 替代藥物 (137)
- 生殖風險 (218)
- 全部 (3869)

1-15 / 295 以下項目的結果 "Heart failure"



- Heart failure, acute; Congestive heart failure  
**Disease:** Detailed evidence-based information
- Heart failure, chronic; Congestive heart failure  
**Disease:** Detailed evidence-based information
- Heart failure, acute; Congestive heart failure  
**Disease:** List of essential care interventions (*Clinical Checklist*)
- Heart failure, chronic; Congestive heart failure  
**Disease:** List of essential care interventions (*Clinical Checklist*)
- Heart failure, acute; Congestive heart failure  
**Disease:** Summary topic
- Heart failure, chronic; Congestive heart failure  
**Disease:** Summary topic
- Heart failure, acute; Congestive heart failure - Prevention & Screening  
**Disease:** Detailed evidence-based information
- Heart failure, chronic; Congestive heart failure - Prevention & Screening  
**Disease:** Detailed evidence-based information
- Heart failure, acute; Congestive heart failure - Prevention & Screening  
**Disease:** Summary topic

# 查找疾病

[Home](#)[Drug Interactions](#)[IV Compatibility](#)[Drug ID](#)[Drug Comparison](#)[CareNotes](#)[NeoFax® / Pediatrics](#)[Tox & Drug Product Lookup](#)[RED BOOK](#)[Calculators](#)[Formulary](#)

## Heart failure, acute; Congestive heart failure

[簡要解答](#)[深入解答](#)[全部結果](#)[Definition](#)[Medical History](#)[Findings](#)[Differential Diagnosis](#)[Testing](#)[Treatment](#)[Drug Therapy](#)[Procedural Therapy](#)[Reference](#)

### Definition

請參閱 '深入解答' 瞭解詳細結果。

Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional cardiac abnormality that impairs the ability of the ventricle to fill with or eject blood; acute decompensated HF may include patients with new-onset HF or those with worsening of previously chronic stable HF [1]

[列印](#)

### 相關結果

[Disease Other Titles](#)[臨床檢查表單](#)Micromedex  
Assistant

# 查找疾病-臨床檢查表單

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax<sup>®</sup> / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## Heart failure, acute; Congestive heart failure

- 簡要解答
- 深入解答
- 全部結果

- Definition
- Medical History
- Findings
- Differential Diagnosis
- Testing
- Treatment
  - Drug Therapy
  - Procedural Therapy
- Reference

### Definition

請參閱 '深入解答' 瞭解詳細結果。

Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional abnormality of the heart that impairs its ability to pump blood. HF may include patients with new-onset HF or those with worsening of previously diagnosed HF.

### 臨床檢查表單

- Heart failure, acute; Congestive heart failure

列印

關閉

### 相關結果

- Disease Other Titles
- 臨床檢查表單

Heart failure, acute; Congestive heart failure; acute decompensated

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

列印

+ 全部展開 | - 全部折疊 | ↑ 頁首

ALWAYS DO

Diagnosis  
Treatment  
Disposition

RELATED INFORMATION

Conditions  
Tests & Procedures

REFERENCES

## Heart failure, acute; Congestive heart failure

Clinical Checklist

Always Do

### Diagnosis

#### Diagnostic Testing

Obtain a 12-lead ECG and chest radiographs (posteroanterior and lateral) in all patients presenting with heart failure [1].

In a patient presenting with heart failure, obtain a 2-dimensional echocardiogram with Doppler to assess left ventricular ejection fraction, left ventricular size, wall thickness, and valve function [1].

In patients who present with dyspnea, measure blood levels of B-type natriuretic peptide (BNP) or N-terminal-proBNP (NT-proBNP) to support or exclude a diagnosis of heart failure \*142[2].

In the initial evaluation of patients with acute heart failure, include CBC, urinalysis, serum electrolytes with calcium and magnesium, BUN, serum creatinine, fasting blood glucose or HbA1C, fasting lipid profile, liver function test panel, and TSH assay [1].

#### Clinical Examination

Perform a thorough history and physical examination in patients presenting with heart failure (HF) to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the progression of HF [1].

# 搭配專業術語查詢

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

用來治療頭痛的藥

Search drug, disease, toxicology and more

Q Drugs that treat headache

X →

Headache

Drugs that treat Headache

Drugs that cause Headache

Headache & Migraine

Headache & Migraine L77

Headache and Nausea Remedy

Headache associated with sexual activity

Micromedex Assistant

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary



## Drugs That Treat Headache

顯示： Effective (7) | Evidence Favors Efficacy (38) | Evidence is Inconclusive (3) | Ineffective (0) | Not Rated (0)

將檢索結果，依證據等級分類

Displaying 48 results for "Drugs That Treat Headache"

Effective (7 results)


藥物名稱	Indication	年齡組別
<a href="#">Amitriptyline Hydrochloride</a>	Tension-type headache; Prophylaxis	Adult
<a href="#">Aspirin</a>	Headache	Adult, Pediatric
<a href="#">Caffeine</a>	Headache; Adjunct	Adult
<a href="#">Galcanezumab-gnlm</a>	Episodic cluster headache	Adult
<a href="#">Ibuprofen</a>	Headache	Adult
<a href="#">Naproxen Sodium</a>	Headache	Adult, Pediatric
<a href="#">SUMAtriptan succinate</a>	Cluster headache	Adult

點擊藥品名稱，可進入藥品資訊



Evidence Favors Efficacy (38 results)


Evidence is Inconclusive (3 results)

# 工具好幫手

Home 	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax® / Pediatrics	Tox & Drug Product Lookup	RED BOOK	Calculators	Formulary	
--	-------------------	------------------	---------	-----------------	-----------	----------------------	---------------------------	----------	-------------	-----------	--

Search drug, disease, toxicology and more

 Drug name or keyword search 

Micromedex Assistant 



# 案例參考

- 張女士是一位75歲女性患有心房顫動合併高血壓的病人，目前服用5mg/day 的Warfarin作為中風的預防，因年歲高視力不佳，家人購買藍莓的營養補充品，希望改善視力、保護老人家心血管健康。後來又因背痛請家人幫忙購買止痛藥，由於服用Aspirin會導致胃部不適，張女士的家人改購買了200mg Ibuprofen；該病患在回診時前來醫院藥局詢問可以同時服用Warfarin、Ibuprofen及藍莓營養補充品嗎？

# 藥物相互作用

- Home
- Drug Interactions**
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## 藥物相互作用

在搜尋欄位鍵入藥物名稱 (包括通用名稱) 選擇藥物後按一下  (新增) 按鈕。

輸入搜尋詞:

相符的藥物名稱: (3)

- Warfarin
- Warfarin Sod
- Warfarin Sodium

保健食品：  
歐越莓/  
山桑子/  
覆盆子

要檢查的藥物：

- Bilberry
- Ibuprofen
- Warfarin

日常用藥：  
止痛藥

治療用藥：  
AF, 高血壓

添加過敏

添加過敏

帶有星號 (\*) 的字母大寫項目表示過敏。

清除

新增過敏症狀。

在搜尋欄位中鍵入過敏症狀。選擇過敏症狀並按一下 **+** (新增) 按鈕。  
按一下「更新」將您的選擇加入至「藥物相互作用」中「要檢查的藥物」表單。

輸入過敏症狀:

asp

相符的過敏症狀: (7)

ASPARAGINASE  
ASPARAGINE  
ASPARAGUS  
ASPARTIC ACID  
ASPERGILLUS FUMIGATUS  
ASPIRIN INTOLERANCE  
**ASPIRIN**

要檢查的過敏症狀:

ASPIRIN  
SEAFOOD

取消

更新

選擇藥物並按一下 **+** (新增) 按鈕。

添加過敏

要檢查的藥物:

添加過敏

Bilberry  
Ibuprofen  
Warfarin  
**ASPIRIN\***  
**SEAFOOD\***

Bilberry Extra Strength  
Bilberry Extract  
Bilberry Extract (Beta Carotene/Bilber...  
Bilberry Extract (Bilberry Extract/Bio...  
Bilberry Extract (Bilberry)  
Bilberry Extract/Bioflavonoid/Querceti...

帶有星號 (\*) 的字母大寫項目表示過敏。

清除

提交

- Home
- Drug Interactions**
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

# Drug Interaction Results

← 修改相互作用



細化方式： 藥物：  嚴重性：  文件：  類型：

跳轉到： [藥物 - 藥物 \(2\)](#) | [複方 \(0\)](#) | [過敏症狀 \(1\)](#) | [食物 \(14\)](#) | [乙醇 \(2\)](#) | [實驗室 \(1\)](#) | [抽煙 \(2\)](#) | [懷孕 \(2\)](#) | [哺乳期 \(2\)](#)

## Drug-Drug 相互作用 (2)

藥物：	嚴重性：	文件：	綜述：
<a href="#">IBUPROFEN -- WARFARIN SODIUM</a>	Major	Fair	Concurrent use of ANTICOAGULANTS and NSAIDS may result in an increased risk of bleeding.
<a href="#">BILBERRY -- WARFARIN SODIUM</a>	Moderate	Fair	Concurrent use of BILBERRY and ANTICOAGULANTS may result in increased risk of bleeding.

嚴重性  
等級不同

Warfarin分別和Ibuprofen、歐越莓併用皆會增加出血風險


## 複方 (未找到)

## Drug-過敏症狀 相互作用 (1)

藥物：	嚴重性：	文件：	綜述：
<a href="#">IBUPROFEN -- ASPIRIN</a>	Unavailable	Unavailable	CROSS-REACTIVITY MAY OCCUR AMONG NSAIDS, AND BETWEEN NSAIDS AND SALICYLATES (ASPIRIN).

## Drug-食物 相互作用 (14)

藥物：	嚴重性：	文件：	綜述：
<a href="#">WARFARIN SODIUM</a>	Major	Excellent	Concurrent use of WARFARIN and VITAMIN K1 may result in altered anticoagulant effectiveness.



## 定義

嚴重性：



**禁忌**

禁止同時使用這些藥物。



**嚴重**

這種相互作用可能危及生命和/或需要醫療干預以儘量減少或避免嚴重的不良影響。



**中等**

這種相互作用可能導致加重患者的病情和/或需要在治療中發生改變。



**較弱**

這種相互作用將限制臨床效果。表現可能包括增加副作用的頻率或嚴重程度，但一般不需要在治療中發生重大改變。



**未知**

未知。

- Home
- Drug Interactions**
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax<sup>®</sup> / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

Drug Interaction Results ← 修改相互作用



細化方式： 藥物：  嚴重性：  文件：  類型：

跳轉到： [藥物-藥物 \(2\)](#) | [複方 \(0\)](#) | [過敏症狀 \(1\)](#) | [食物 \(14\)](#) | [乙醇 \(2\)](#) | [實驗室 \(1\)](#) | [抽煙 \(2\)](#) | [懷孕 \(2\)](#) | [哺乳期 \(2\)](#)

**Drug-Drug 相互作用 (2)**

藥物：	嚴重性：	文件：	綜述：
<a href="#">IBUPROFEN -- WARFARIN SODIUM</a>	Major	Fair	Concurrent use of ANTICOAGULANTS and NSAIDS may result in an increased risk of bleeding.
<a href="#">BILBERRY -- WARFARIN SODIUM</a>	Moderate	Fair	Concurrent use of BILBERRY and ANTICOAGULANTS may result in increased risk of bleeding.

複方 (未找到)


查看細節的臨床處置與案例

**Drug-過敏症狀 相互作用 (1)**

藥物：	嚴重性：	文件：	綜述：
<a href="#">IBUPROFEN -- ASPIRIN</a>	Unavailable	Unavailable	CROSS-REACTIVITY MAY OCCUR AMONG NSAIDS, AND BETWEEN NSAIDS AND SALICYLATES (ASPIRIN).

**Drug-食物 相互作用 (14)**

藥物：	嚴重性：	文件：	綜述：
<a href="#">WARFARIN SODIUM</a>	Major	Excellent	Concurrent use of WARFARIN and VITAMIN K <sub>1</sub> may result in altered anticoagulant effectiveness.



INTERACTION DETAIL

**Warning:**

Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.

**Clinical Management:**

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

**Onset:**

Not Specified

INTERACTION DETAIL

Major

**Documentation:**

Fair

**Probable Mechanism:**

additive effect on hemostasis

**Summary:**

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

列印  關閉 

- Home
- Drug Interactions**
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

### Drug Interaction Results

修改相互作用

細化方式： 藥物： All 嚴重性： 2 (Selected) 文件： All 類型： All

跳轉到： 藥物-藥物 (1) | 食物 (5) | 乙醇 (1) | 抽煙 (2) | 懷孕 (2)

選中/取消選中以細化嚴重性設定。

全部選中 | 全部不選

- Contraindicated
- Major
- Moderate
- Minor
- Unknown

取消 更新

藥物：	嚴重性：	文件：	綜述：
<b>Drug-Drug 相互作用 (1)</b>			
IBUPROFEN – WARFARIN SODIUM	<b>S</b> Major	Fair	Concurrent use of ANTICOAGULANTS and NSAIDS may result in an increased risk of bleeding.
<b>Drug-食物 相互作用 (5)</b>			
WARFARIN SODIUM	<b>S</b> Major	Excellent	Concurrent use of WARFARIN and VITAMIN K FOODS may result in altered anticoagulant effectiveness.
WARFARIN SODIUM	<b>S</b> Major	Fair	Concurrent use of WARFARIN and GRAPEFRUIT JUICE may result in increased warfarin exposure and an increased INR.
WARFARIN SODIUM	<b>S</b> Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.
WARFARIN SODIUM	<b>S</b> Major	Fair	Concurrent use of WARFARIN and CAFFEINE may result in increased warfarin exposure and an increased INR.
WARFARIN SODIUM	<b>S</b> Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
<b>Drug-乙醇 相互作用 (1)</b>			
IBUPROFEN	<b>S</b> Major	Fair	Concurrent use of IBUPROFEN and ETHANOL may result in an increased risk of serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation.
<b>Drug-抽煙 相互作用 (2)</b>			
IBUPROFEN	<b>S</b> Major	Fair	Concurrent use of IBUPROFEN and TOBACCO may result in an increased risk of serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation.
WARFARIN SODIUM	<b>S</b> Major	Excellent	Concurrent use of WARFARIN and TOBACCO may result in reduced warfarin exposure and reduced INR.
<b>Drug-懷孕 相互作用 (2)</b>			

# 案例參考

- 王先生，退休教師，有以下病史：類風濕性關節炎 (Rheumatoid Arthritis, RA)、慢性腎臟病 (Chronic Kidney Disease, CKD)、心臟衰竭 (Heart Failure)、深層靜脈栓塞 (Deep Vein Thrombosis, DVT)，一日，王先生突然感到胸部劇痛，呼吸困難，立刻緊急送醫。



# 案例參考

- 急診室評估在急診室，醫療團隊立即對王先生進行了詳細評估。  
根據他的病史和症狀，醫師懷疑他可能患上了肺栓塞  
( Pulmonary Embolism )，這是一種由深層靜脈栓塞引起的危及生命的併發症，經過檢查確診為肺栓塞。

# 多個藥物的IV相容性

The screenshot shows the Micromedex IV Compatibility tool interface. At the top, the Micromedex logo is visible. Below it is a navigation menu with options: Home, Drug Interactions, IV Compatibility (highlighted with a yellow box), Drug ID, and Drug Comparison. The main heading is "IV Compatibility". Below the heading, there is a prompt: "Add at least one drug and press View Compatibility". Underneath, it says "Drugs (2345)". There is a search bar labeled "Find a Drug" with an information icon (i) to its right. Below the search bar, four drug names are listed in dark grey buttons with 'x' icons: Anakinra, ceFAZolin sodium, Furosemide, and Heparin Sodium. Below these buttons, there is a search bar labeled "Find a Solution" with an information icon (i) to its right. At the bottom, there are two buttons: "View Compatibility" (highlighted with a yellow box and a right-pointing arrow) and "Clear All".

輸入至少一種藥品

治療類風濕性關節炎

治療多種病原細菌的抗細菌藥

治療因心臟衰竭引起的水腫

自然抗凝血劑

需要時輸入溶液

切換呈現結果

- Preparation and Storage**
- Drugs:
- Anakinra
  - ceFAZolin sodium
  - Furosemide
  - Heparin Sodium

- Filter results**
- Administration Method
- Y-Site
  - Admixture
  - Syringe

- Compatibility
- Compatible
  - Incompatible
  - Uncertain
  - No Data

Drugs

All (4)

**Apply Filters**

Reset Filters

Drug-Drug Drug-Solution TPN

Drug	Anakinra	ceFAZolin sodium	Furosemide	Heparin Sodium
Anakinra		Y-Site 2 Results	Y-Site No Data	Y-Site No Data
ceFAZolin sodium	Y-Site 2 Results		Y-Site 4 Results	Y-Site 7 Results
Furosemide	Y-Site No Data	Y-Site 4 Results		Y-Site 11 Results
Heparin Sodium	Y-Site No Data	Y-Site 7 Results	Y-Site 11 Results	

Page View: Chart List

Powered by Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility).

IV Index contains the Confidential Information of BAXTER HEALTHCARE CORPORATION. Use of IV Index or information which it contains by anyone other than an expressed licensee is strictly prohibited.



IV Compatibility Results Detail

**Drug-Drug Y-Site Test Results**

✔ Heparin Sodium - Furosemide

Results: 11

^ Collapse All

✔ Study 1

Drug 1:	<b>Furosemide</b> 0.16 mg/mL 'in' Dextrose 5% in Water Manufacturer Unspecified
Drug 2:	<b>Heparin Sodium</b> 40 units/mL 'in' Dextrose 5% in Water British Pharmacopoeia formulation tested
Status:	✔
Information:	<b>Physical Compatibility:</b> Physically compatible. No visible haze or particulate formation, color change, or gas evolution. <b>Storage:</b> Room temperature of 20 °C.
Test Parameters:	<b>Container:</b> The test sample container was not cited. <b>Study Period:</b> 3 hours. <b>Method:</b> Visual observation. <b>Reference:</b> 1168

提供藥物與溶液泡製、存放的細節資訊

Filter results Key

✔ Study 2

Drug 1:	<b>Furosemide</b> 5 mg/mL 'in' Normal saline- Sodium chloride 0.9%
---------	---

Micromedex Assistant

Home

Drug Interactions

**IV Compatibility**

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

Preparation and Storage

Drugs:

- [Anakinra](#)
- [ceFAZolin sodium](#)
- [Furosemide](#)
- [Heparin Sodium](#)

Filter results

Administration Method

- Y-Site
- Admixture
- Syringe

Compatibility

- Compatible
- Incompatible
- Uncertain
- No Data

Drugs

All (4) ▼

Apply Filters

Reset Filters

Drug-Drug **Drug-Solution** TPN

Page View: **Chart** List

Relevant Common Solution(s) Results

IV Solution	Anakinra	ceFAZolin sodium	Furosemide	Heparin Sodium
1/2 NS Sodium chloride 0.45%	Solution No Data  Y-Site No Data	Solution No Data  Y-Site No Data	Solution No Data  Y-Site No Data	Solution 2 Results  Y-Site No Data
D10W Dextrose 10% in water	Solution No Data  Y-Site No Data	Solution 2 Results  Y-Site No Data	Solution 1 Result  Y-Site No Data	Solution 2 Results 1 Result  Y-Site No Data
D5LR Dextrose 5% in lactated Ringers	Solution No Data  Y-Site No Data	Solution 3 Results  Y-Site No Data	Solution 1 Result  Y-Site No Data	Solution 3 Results  Y-Site No Data
D5NS Dextrose 5% in sodium chloride 0.9%	Solution No Data	Solution 2 Results	Solution No Data	Solution 7 Results 1 Result

- Home
- Drug Interactions
- IV Compatibility**
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

- Preparation and Storage**
- Drugs:**
- [Anakinra](#)
  - [ceFAZolin sodium](#)
  - [Furosemide](#)
  - [Heparin Sodium](#)

**Filter results**

Administration Method

- Y-Site
- Admixture
- Syringe

Compatibility

- Compatible
- Incompatible
- Uncertain
- No Data

Drugs

All (4)

**Apply Filters**

Reset Filters

- Drug-Drug
- Drug-Solution
- TPN**

Page View: Chart List

## TPN (2-in-1) Results Summary TPN Information

Drug	Notes	Results
ceFAZolin sodium 1 mg/mL	One simple TPN admixture was used in this testing having the following composition per liter: FreAmine® II 4.25% Dextrose 25%	Admixture 1 Result
ceFAZolin sodium 1 mg/mL	One neonatal TPN admixture was used in this testing having the following composition per liter: Amino acids 1.5% (Baxter) Dextrose 15% Unspecified electrolytes and vitamins	Admixture 1 Result
ceFAZolin sodium 1.2 g/5.3 mL	One TPN admixture was used in this testing having the following composition per liter:  Aminosyn 3% Dextrose 20% Sodium chloride 30 mEq Potassium chloride 25 mEq Calcium gluconate 15 mEq Potassium phosphates 15 mmol Magnesium sulfate 10 mEq M.V.I. 2 mL Trace elements	Y-Site 1 Result
ceFAZolin sodium 10 mg/mL	One TPN admixture was used in this testing having the following composition: Travasol® 4.25% (with electrolytes) Dextrose 16.65% Sodium chloride 55 mEq Potassium chloride 70 mEq	Admixture 1 Result

Micromedex Assistant

# 藥物鑒定 用印碼查詢

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

## 藥物鑒定

搜尋：按照印碼 | [無印碼? 按一下此處按以下條件搜尋說明](#) ▶

側面 1：  部分印記

側面 2：  部分印記

清除

搜尋

# 藥物鑒定 印碼查找結果

- Home
- Drug Interactions
- IV Compatibility
- Drug ID**
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## 藥物鑒定結果

← 修改鑒定

搜尋圖像 ▶

列印

2 以下項的相符項: "mrk, 74"

按以下項排序所有結果: **印記** ▼

2 藥物相符 用於 'M'

1 - 2 (2 相符的藥物) ◀ 第一個 ◀ 前面 | 後面 ▶ 最後一個 ▶▶

顯示: ALL | 0-9 | A | B | C | D | E | F | G | H | I | J | K | L | **M** | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

印記 ▼	藥物名稱	製造商	可用性	AAPCC	Poisindex 管理
Mrk; 74; Vioxx	Vioxx	Merck Frosst	Canada	201065	COX-2 INHIBITORS
Mrk; 74; Vioxx	Vioxx	Merck & Company	United States	201065	COX-2 INHIBITORS

# 藥物鑒定 印碼查找結果

藥物資訊

執行 Tox 和藥物產品查找: [Hyzaar 100-25 ▶](#)  
 執行 Martindale 藥物產品查找: [Hyzaar 100-25 ▶](#)

藥物名稱: HYZAAR 100-25  
 成分: HYDROCHLOROTHIAZIDE -- 25 MG  
 LOSARTAN -- 100 MG

相關文件: [POISINDEX MANAGERMENTS - ANGIOTENSIN II ANTAGONISTS](#)  
[POISINDEX MANAGERMENTS - DIURETICS](#)  
[DRUGDEX EVALUATIONS - LOSARTAN](#)  
[DRUGDEX EVALUATIONS - HYDROCHLOROTHIAZIDE](#)

顏色: LIGHT YELLOW	NDC: 00006-0747-81
形狀: TEARDROP-SHAPE	00006-0747-31
印記: MRK 747 ; HYZAAR	00006-0747-82
劑型: ORAL TABLET	00006-0747-54
	00006-0747-28
可用容器大小: BOTTLE OF 1000 , BOTTLE OF 90 , STRIP OF 100 , BOTTLE OF 4000 , BOTTLE OF 30	輔料: D&C YELLOW NO. 10 ALUMINUM LAKE ; HYDROXYPROPYL CELLULOSE ; HYPROMELLOSE ; LACTOSE, HYDROUS ; MAGNESIUM STEARATE ; MICROCRYSTALLINE CELLULOSE ; PREGELATINIZED STARCH
AAPCC 代碼: 310109 - ANGIOTENSIN RECEPTOR BLOCKER IN COMBINATION WITH DIURETIC	監管狀態: RX

列印 關閉 X

藥物資訊

RECEPTOR BLOCKER IN COMBINATION WITH  
 DIURETIC

監管狀態: RX  
 可用性: UNITED STATES  
 產品 ID 5724722  
 聯絡資訊: MERCK SHARP & DOHME LLC



列印 關閉 X

# 藥物鑒定 用外觀查詢

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

## 藥物鑒定

搜尋：按照說明 [按一下此處按以下條件搜尋印碼](#)

- Black
- Blue
- Brown
- Clear
- Gold
- Gray
- Green
- Off-White
- Orange
- Pink
- Purple
- Red
- Tan
- White
- Yellow

形狀： Egg-shape

圖譜： All Patterns

顯示帶結果的圖像

清除

搜尋

Micromedex

Monograph search Q Keyword search

Feedback Mobile access User account Logout





Home Drug Interactions IV Compatibility **Drug ID** Drug Comparison CareNotes NeoFax® / Pediatrics Tox & Drug Product Lookup RED BOOK Calculators Formulary

### 藥物鑒定結果

4 以下項的相符項： "Egg-shape, All Patterns, Pink" [按以下項排序所有結果： 印記](#)

4 藥物相符 用於 'A' 1 · 4 (4 相符的藥物) [← 第一個](#) [← 前面](#) | [後面](#) [→ 最後一個](#)

顯示： ALL | 0-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

隱藏圖像	印記	藥物名稱
	a ET	Erythrocin Stearate Filmtab
	a ET	Erythrocin Stearate Filmtab
	a PCE	PCE Dispertab
	a PCE	PCE Dispertab

Micromedexolutions.com ^ Support ^ Latest News

Micromedex Assistant

# 藥物比較

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox &amp; Drug Product Lookup

RED BOOK

Calculators

Formulary

## 藥物比較

在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 **>**（新增）按鈕。

輸入搜尋詞：

相符的藥物名稱: (1)

Warfarin Sodium

要檢查的藥物：

Dabigatran Etexilate Mesylate  
Rivaroxaban  
Warfarin Sodium



清除

提交



Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

## Drug Comparison Results

修改比較

列印

在欄中顯示 1

在欄中顯示 2

Dabigatran Etexilate Mesylate

Rivaroxaban

更新

跳轉到：[↑ 頁首](#) | [Dosing & Indications](#) | [Boxed Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

### FDA-Labeled Indications

檢視 DRUGDEX 中的詳細資訊

**Atrial fibrillation, Nonvalvular - Cerebrovascular accident; Prophylaxis - Embolism, Systemic; Prophylaxis**

**FDA Approval:**

- Adult, yes
- Pediatric, no

**Efficacy:**

- Adult, Effective

**Strength of Recommendation:**

- Adult, [Class IIa](#)

**Strength of Evidence:**

- Adult, [Category B](#)

**Postoperative deep vein thrombosis; Prophylaxis - Total replacement of hip**

**FDA Approval:**

- Adult, yes

### FDA-Labeled Indications

檢視 DRUGDEX 中的詳細資訊

**Atrial fibrillation, Nonvalvular - Cerebrovascular accident; Prophylaxis - Embolism, Systemic; Prophylaxis**

**FDA Approval:**

- Adult, yes
- Pediatric, no

**Efficacy:**

- Adult, Effective

**Strength of Recommendation:**

- Adult, [Class IIa](#)

**Strength of Evidence:**

- Adult, [Category B](#)

**Congenital heart disease - Fontan operation, Recent history of - Thrombosis;**

**FDA Approval:**

- Adult, no

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison**
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

在欄中顯示 1

Dabigatran Etxilate Mesylate

在欄中顯示 2

Rivaroxaban

更新

- 跳轉到：[頁首](#) | [Dosing & Indications](#) | [Boxed Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | **[Adverse Effects](#)** | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

## Adverse Effects

檢視 DRUGDEX 中的詳細資訊 ▶

### Common

- **Gastrointestinal:** Esophagitis, Gastritis, Gastroesophageal reflux disease (Atrial fibrillation, 5.5% ), Gastrointestinal hemorrhage (Adult, DVT and pulmonary embolism, 0.7% to 3.1%; adult, nonvalvular atrial fibrillation, 6.1% ; pediatric, 5.7% ), Gastrointestinal ulcer, Indigestion (Adult, DVT and pulmonary embolism, 4.1% to 7.5% ; pediatric, 5% to 9% )
- **Hematologic:** Hemorrhage (Adult, DVT and pulmonary embolism treatment or prophylaxis, 9.7% to 12.3%; adult, nonvalvular atrial fibrillation, 16.6% ; pediatric, 20% to 22% )

### Serious

- **Cardiovascular:** Myocardial infarction (DVT and pulmonary embolism, 0.1% to 0.66%; nonvalvular atrial fibrillation, 0.7% )
- **Gastrointestinal:** Gastrointestinal hemorrhage, Major (DVT and pulmonary embolism, 0.1% to 0.6%; nonvalvular atrial fibrillation, 1.6% ), Upper gastrointestinal bleeding
- **Hematologic:** Hemorrhage, Major (Adult, DVT and pulmonary embolism, 0.3% to 2%; adult, nonvalvular atrial fibrillation, 3.3% ; pediatric, 1.4% to 2.3% ), Thrombosis
- **Immunologic:** Anaphylaxis
- **Neurologic:** Epidural hematoma, Intracranial hemorrhage (Nonvalvular atrial fibrillation, 0.3%; DVT and pulmonary embolism, 0.1% ), Traumatic spinal subdural hematoma
- **Respiratory:** Hemorrhage, Alveolar

## Adverse Effects

檢視 DRUGDEX 中的詳細資訊 ▶

### Common

- **Gastrointestinal:** Gastroenteritis (12.5%), Vomiting (10.6% to 14.1%)
- **Hematologic:** Hemorrhage (DVT prophylaxis following hip or knee replacement, 5.8%; treatment of DVT or pulmonary embolism, 28.3%; reduction in risk of recurrence of DVT or pulmonary embolism, 13.4%; prophylaxis of VTE in acutely ill medical patients, 2.9%; VTE treatment and reduction in risk of recurrent VTE, 36.2% )
- **Respiratory:** Cough (15.6%)

### Serious

- **Gastrointestinal:** Gastrointestinal hemorrhage (0.7% to 2%), Upper gastrointestinal bleeding
- **Hematologic:** Hematoma, Epidural or spinal, Hemorrhage, Major (Stroke prevention in nonvalvular atrial fibrillation, 3.6%; DVT prophylaxis following hip or knee replacement, 0.3%; treatment of DVT or pulmonary embolism, 1%; reduction in risk of recurrence of DVT or pulmonary embolism, 0.4%; prophylaxis of VTE in acutely ill medical patients, 0.7%; thromboprophylaxis in patients with congenital heart disease, 1.6%; risk reduction of major cardiovascular events in peripheral artery disease, 1.9%; risk reduction of major cardiovascular events in chronic coronary artery disease, 1.6%)
- **Immunologic:** Angioedema
- **Other:** Substance withdrawal, Stroke and non-CNS embolism

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison**
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

在欄中顯示 1

Dabigatran Etexilate Mesylate

在欄中顯示 2

Rivaroxaban

- Dabigatran Etexilate Mesylate
- Rivaroxaban
- Warfarin Sodium**

更新

跳轉到：[↑ 頁首](#) | [Dosing & Indications](#) | [Boxed Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(selected\)](#) | [Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#)  
[Toxicology](#) | [Clinical Teaching](#) | [References](#)

## Dabigatran Etexilate Mesylate

檢視 DRUGDEX 中的詳細資訊 ▶

### Dosing & Indications

#### Adult Dosing

檢視 DRUGDEX 中的詳細資訊 ▶

#### Important Note

- Dabigatran etexilate mesylate is available in 2 dosage forms (oral capsules and oral pediatric pellets) that vary in approved indications and age groups. These dosage forms cannot be used interchangeably due to differences in bioavailability. Do not substitute dosage forms on a milligram-to-milligram basis and do not combine more than one dosage form to achieve the total dose [1][2].
- Evaluate renal function prior to therapy [3].

#### General Dosage Information

- If anticoagulation activity needs to be assessed, may use activated partial thromboplastin time (aPTT) or ecarin clotting time (ECT), but not INR [4]
- Switching to dabigatran from another direct oral anticoagulant (DOAC), low molecular weight heparin (LMWH), or fondaparinux: Initiate dabigatran 0 to 2 hours prior to the next scheduled

## Rivaroxaban

檢視 DRUGDEX 中的詳細資訊 ▶

### Dosing & Indications

#### Adult Dosing

檢視 DRUGDEX 中的詳細資訊 ▶

#### General Dosage Information

- Switching to rivaroxaban from another direct oral anticoagulant (DOAC) [1], low molecular weight heparin (LMWH), or fondaparinux [2]: Initiate rivaroxaban 0 to 2 hours prior to the next scheduled dose of the original anticoagulant, then discontinue the original anticoagulant [1][2].
- Switching to rivaroxaban from unfractionated heparin: From IV unfractionated heparin, discontinue IV unfractionated heparin infusion and initiate rivaroxaban immediately [3] or within 30 minutes. From subQ unfractionated heparin, discontinue subQ unfractionated heparin and initiate rivaroxaban about 4 to 5 hours after the last dose of subQ unfractionated heparin [2] or from intermittent IV administration of heparin, start rivaroxaban 0 to 2 hours before the time that the next dose of heparin was to have been administered [4].
- Switching to rivaroxaban from warfarin: Discontinue warfarin and initiate rivaroxaban when INR is less than 3 [1][2]. As a general rule, start DOAC when INR drops below 2.5; 2.5 to 3.5 or higher, initiate when INR is close to lower end of target range [2].

# CareNotes

Home 

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics


Tox & Drug Product Lookup

RED BOOK


Calculators

Formulary

Search drug, disease, toxicology and more

 Drug name or keyword search



Micromedex Assistant 

Location:



Print List (0)

- 1 Search
- 2 Select Titles
- 3 Select Documents
- 4 Customize (optional)
- 5 Print

Learn how to boost your HCAHPS scores with [Medication Essential Fact Sheets](#)

### Keyword Search

Search:

Feedback



# NeoFax / Pediatrics

Home | Drug Interactions | IV Compatibility | Drug ID | Drug Comparison | CareNotes | **NeoFax® / Pediatrics** | Tox & Drug Product Lookup | RED BOOK | Calculators | Formulary

**Drug Monographs** | Enteral Formulas | Dosing Calculators | **What's New**

切換新生兒/幼兒類別，會有不同的藥物選單

## Drug Monographs

Drug Neonatal Pediatric

Find a Neonatal drug

- 5-FC
- Abacavir
- Abelcet
- Acetadote
- Acetaminophen
- Acetate
- AcetaZOLAMIDE
- Acetylcysteine
- ActHIB
- Acticlate

Drug Neonatal Pediatric

Find a Pediatric drug

- 5-FC
- Abacavir
- Abacavir/Dolutegravir/Lamivudine
- Abacavir/Lamivudine
- Abametapir
- Abatacept
- Abciximab
- Abelcet
- Abilify
- Abilify Discmelt

NeoFax® / Pediatrics What's New Content

Content updates for NeoFax®:

Content updates:

- Abacavir
- Ciprofloxacin
- Emtricitabine
- Immune Globulin (Human)
- Lamivudine
- Lopinavir/Ritonavir
- Maraviroc
- Nevirapine
- Raltegravir
- Zidovudine

Content updates for Pediatrics™:

Content updates:

- Abacavir
- Abacavir/Dolutegravir/Lamivudine
- Abacavir/Lamivudine
- Adalimumab-atto
- Atazanavir
- Atazanavir/Cobicistat
- Bictegravir/Emtricitabine/Tenofovir Alafenamide
- Cabotegravir
- Cabotegravir/Rilpivirine
- Ciprofloxacin
- Cobicistat
- Darunavir
- Darunavir/Cobicistat

新生兒/幼兒新用藥

## Vancomycin

Neonatal

Pediatric

在單一藥品頁面，仍可切換新生兒 / 兒童類別

### Drug

Find a Neonatal drug

### Dosing/ Administration

Dose

Uses

Administration

### Medication Safety

Contraindications/ Precautions

Adverse Effects

Solution Compatibility

Terminal Injection Site Compatibility

Terminal Injection Site Incompatibility

Monitoring

### Mechanism Of Action/ Pharmacokinetics

Pharmacology

### About

Special Considerations/ Preparation

References

### Dosing/ Administration

#### Dose

**Usual dosage:** 10 to 15 mg/kg/dose IV every 6 to 18 hours

檢視完整文件

列印

Initial Dose Intervals		
PMA†	Postnatal Age†	Interval
29 weeks or less	0 to 14 days	18 hours
	older than 14 days	12 hours
30 to 36 weeks	0 to 14 days	12 hours
	older than 14 days	8 hours
37 to 44 weeks	0 to 7 days	12 hours
	older than 7 days	8 hours
45 weeks or more	ALL	6 hours

† Postmenstrual age (PMA) is gestational age plus postnatal age. PMA is the primary determinant of dosing interval with postnatal age as the secondary qualifier. Renal function and drug elimination are strongly correlated with postmenstrual age.

**Serious MRSA infections:** 10 to 20 mg/kg/dose IV every 8 to 48 hours depending on postmenstrual age, weight, and serum creatinine; adjust dose to achieve desired AUC/MIC ratio. **Maximum 3600 mg/day;** most children do not require doses higher than 3000 mg/day [1].

#### Anthrax, cutaneous or systemic

**32 to less than 34 weeks gestational age and 0 to 4 weeks of chronologic age:** 20 mg/kg/dose IV loading dose, then 15 mg/kg/dose IV every 12 hours; after dose 3, adjust to target vancomycin AUC of 400 mcg x hr/mL, or trough of 10 to 15 mcg/mL if AUC monitoring is not available [2].

**34 weeks gestational age or older and 0 to 4 weeks of chronologic age:** 20 mg/kg/dose IV loading dose, then 15 mg/kg/dose IV every 8 hours; after dose 3, adjust to target vancomycin AUC of 400 mcg x hr/mL, or trough of 10 to 15 mcg/mL if AUC monitoring is not available [2].

**Duration of therapy, cutaneous anthrax:** 7 to 10 days or until clinically stable. If aerosol exposure occurred or is suspected, transition to a postexposure prophylaxis regimen after completion of the treatment

可再由右上角切換藥物資訊頁面

Drug

- Find a Neonatal drug
- 5-FC
- Abacavir
- Abelcet
- Acetadote**
- Acetaminophen
- Acetate
- AcetaZOLAMIDE
- Acetylcysteine
- ActHIB
- Acticate

## Vancomycin

Neonatal

Pediatric

Dosing/ Administration

Dose

Uses

Administration

Medication Safety

Contraindications/ Precautions

Adverse Effects

Solution Compatibility

Terminal Injection Site Compatibility

Terminal Injection Site Incompatibility

Monitoring

Mechanism Of Action/ Pharmacokinetics

Pharmacology

About

Special Considerations/ Preparation

References

### Dosing/ Administration

#### Dose

**Usual dosage:** 10 to 15 mg/kg/dose IV every 6 to 18 hours

Initial Dose Intervals	
PMA†	Postnatal Age†
29 weeks or less	0 to 14 days older than 14 days
30 to 36 weeks	0 to 14 days older than 14 days
37 to 44 weeks	0 to 7 days older than 7 days
45 weeks or more	ALL

† Postmenstrual age (PMA) is gestational age plus postnatal age. PMA is the primary determinant of dosing interval with postnatal age as the secondary qualifier. Renal function and drug elimination are strongly correlated with postmenstrual age.

**Serious MRSA infections:** 10 to 20 mg/kg/dose IV every 8 to 48 hours depending on postmenstrual age, weight, and serum creatinine; adjust dose to achieve desired AUC/MIC ratio. **Maximum 3600 mg/day;** most children do not require doses higher than 3000 mg/day [1].

**Anthrax, cutaneous or systemic**

**32 to less than 34 weeks gestational age and 0 to 4 weeks of chronologic age:** 20 mg/kg/dose IV loading dose, then 15 mg/kg/dose IV every 12 hours; after dose 3, adjust to target vancomycin AUC of 400 mcg x hr/mL, or trough of 10 to 15 mcg/mL if AUC monitoring is not available [2].

**34 weeks gestational age or older and 0 to 4 weeks of chronologic age:** 20 mg/kg/dose IV loading dose, then 15 mg/kg/dose IV every 8 hours; after dose 3, adjust to target vancomycin AUC of 400 mcg x hr/mL, or trough of 10 to 15 mcg/mL if AUC monitoring is not available [2].

**Duration of therapy, cutaneous anthrax:** 7 to 10 days or until clinically stable. If aerosol exposure occurred or is suspected, transition to a postexposure prophylaxis regimen after completion of the treatment

Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes **NeoFax® / Pediatrics** Tox & Drug Product Lookup RED BOOK Calculators Formulary

Drug Monographs **Enteral Formulas** Dosing Calculators What's New

## Enteral Formula Comparison

## 新生兒 / 兒童腸道配方比較

Neonatal **Pediatric**

選擇數量比例

Select the required population type, display format, choose a formula and select the  button. Select the  button to remove items from the list.

Display Format:  Per 100 Cal  Per Liter  Per Both

輸入腸道營養配方名稱

Enter search term:

- Formulas Available: (59)**
- Dr Brown's Good Start® GentlePro™
  - Dr Brown's Good Start® SoothePro™
  - Dr Brown's Good Start® Soy-Ease Pro™
  - EleCare® for Infants
  - Enfamil NeuroPro™ EnfaCare®
  - Enfamil NeuroPro™ EnfaCare® Powder in Breast Milk
  - Enfamil® 24
  - Enfamil® A.R.®
  - Enfamil® Gentlelease®
  - Enfamil® Infant
  - Enfamil® Premature 20
  - Enfamil® Premature 24 Cal
  - Enfamil® Premature 24 Cal HP
  - Enfamil® Premature 30
  - Enfamil® ProSobee®
  - Enfamil® Reguline™
  - Glutarex®-1

- Formulas Selected:** (Maximum of 3 formulas can be selected)
- Neocate® Infant DHA/ARA
  - Pregestimil® 24
  - PTHM + Enfamil® Liquid Human Milk Fortifier Standard ...

最多三項進行比較

選擇其中一項後點擊 **Product Notes** 會出現產品資訊

Clear **Product Notes** Display

Product Notes - MICROMEDEX - Google Chrome

about:blank

### Product Notes

**Neocate® Infant DHA/ARA**

Neocate® Infant DHA/ARA

20 Cal/fl oz (see footnotes for preparation)  
Available as powder.  
Hypoallergenic amino acid-based formula for infants with cow milk allergy, multiple food allergies and related GI and allergic conditions.

\* Iron supplementation should be considered for preterm infants.

† Protein Source: L-amino acids.  
‡ Fat Source: Refined Vegetable Oil (medium chain triglycerides (8%), high oleic sunflower oil (6%), sunflower oil (5%), canola oil (4%)).  
§ Carbohydrate Source: Corn syrup solids (54%).

## Enteral Formula Comparison

## 新生兒 / 兒童腸道配方比較

Neonatal **Pediatric**

Select the required population type, display format, choose a formula and select the button. Select the button to remove items from the list.

Display Format:  Per 100 Cal  Per Liter  Per Both

Enter search term:

- Formulas Available: (59)**
- Dr Brown's Good Start® GentlePro™
  - Dr Brown's Good Start® SoothePro™
  - Dr Brown's Good Start® Soy-Ease Pro™
  - EleCare® for Infants
  - Enfamil NeuroPro™ EnfaCare®
  - Enfamil NeuroPro™ EnfaCare® Powder in Breast Milk
  - Enfamil® 24
  - Enfamil® A.R.®
  - Enfamil® Gentlelease®
  - Enfamil® Infant
  - Enfamil® Premature 20
  - Enfamil® Premature 24 Cal
  - Enfamil® Premature 24 Cal HP
  - Enfamil® Premature 30
  - Enfamil® ProSobee®
  - Enfamil® Reguline™
  - Glutarex®-1

- Formulas Selected:** *(Maximum of 3 formulas can be selected)*
- Neocate® Infant DHA/ARA
  - Pregestimil® 24
  - PTHM + Enfamil® Liquid Human Milk Fortifier Standard ...

Clear Product Notes **Display**

Print

Nutrient	Neocate® Infant DHA/ARA	Pregestimil® 24	PTHM + Enfamil® Liquid Human Milk Fortifier Standard Protein 22
	Per 100 cal	Per 100 cal	Per 100 cal
Energy, Cal	100	100	100
Volume, mL	149	123	134.4
Protein, g	2.8	2.8	3
% of total calories †	11.2	11	13
Fat, g	5.1	5.6	5.7
% of total calories ††	45.7	49	50
Linoleic acid, mg	738	940	730
Carbohydrate, g	10.8	10.2	9.6
% of total calories §	43.1	40	37
Water, g	--	108	118
<b>Minerals</b>			
Calcium, mg (mEq)	116 (5.8)	94 (4.7)	101 (5.1)
Phosphorus, mg (mEq)	82.2 (5.3)	52 (3.4)	56 (3.6)
Magnesium, mg	10.6	8	8.9
Iron, mg	1.5*	1.8	1.18*
Zinc, mg	1.1	1	1
Manganese, mcg	41.4	25	6.5
Copper, mcg	84.9	75	83
Molybdenum, mcg	2.3	--	--
Iodine, mcg	20.7	15	22
Selenium, mcg	3	2.8	2.9
Sodium, mg (mEq)	39.1 (1.7)	47 (2)	51 (2.2)
Potassium, mg (mEq)	109 (2.8)	110 (2.8)	89 (2.3)
Chloride, mg (mEq)	79.9 (2.3)	86 (2.4)	88 (2.5)
<b>Vitamins</b>			
Vitamin A, IU	280	350	770
Vitamin D, IU	72.9	50	124
Vitamin E, IU	1.4	4	3.9
Vitamin K, mcg	8.8	12	5.9
Thiamine (B <sub>1</sub> ), mcg	110	80	123
Riboflavin (B <sub>2</sub> ), mcg	110	90	194
Niacin (B <sub>3</sub> ), mcg	110	80	80

# NeoFax / Pediatrics



Monograph search  Keyword search

Feedback Mobile access User account Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics**
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary
- Drug Monographs
- Enteral Formulas
- Dosing Calculators**
- What's New

## Dosing Calculators - Patient Information

Birthdate: (MM/DD/YYYY)

Population Type: **Neonatal**

Gestational Age:  weeks  days

Postnatal Age:  weeks  days

Postmenstrual Age:  weeks  days

Current Weight:  kg

<< Oct >>		2025		X		
Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	

設定新生兒病患出生日期、妊娠週數、出生後週數及體重等

[Proceed to Calculator](#)

# NeoFax / Pediatrics



Monograph search

Q Keyword search

Feedback

Mobile access

User account

Logout

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

Drug Monographs

Enteral Formulas

Dosing Calculators

What's New

## Dosing Calculators - Patient Information

Birthdate: (MM/DD/YYYY)

07/07/2025



Population Type:

Pediatric

Age

3 Months, 14 Days

Current Weight:

5 kg

Proceed to Calculator

設定兒童病患出生日期及體重

Home

Drug Interactions

IV Compatibility

Drug ID

Drug Comparison

CareNotes

NeoFax® / Pediatrics

Tox & Drug Product Lookup

RED BOOK

Calculators

Formulary

Drug Monographs

Enteral Formulas

Dosing Calculators

What's New

## Dosing Calculators - Calculator

Pediatric

### 選擇使用的藥物與途徑

#### CefTRIAxone

##### Drug Use:

- Acute bacterial sinusitis; Initial oral not feasible
- Acute bacterial sinusitis; Severe
- Acute otitis media (1-day regimen)
- Acute otitis media (3-day regimen)
- Bacterial meningitis, once-daily
- Bacterial meningitis, twice-daily
- Community-acquired pneumonia, once-daily

##### Drug Route:

- IM
- IV

3 Months, 14 Days

5 kg

##### Calculator Notes

May administer with 1% lidocaine without epinephrine to reduce pain. Follow with oral therapy in 24 hours, if possible.

##### Pediatrics

50 mg/kg/dose

Single dose

IM

250 to 350 mg/mL

Dose amount

Dose volume

##### Ordered

Dose  mg/kg/dose

Interval

Admin.

Conc.  mg/mL

250 mg/dose

0.71 mL/dose

Change Drug

Reset Form


Calculate

Print

Drug Monograph

Comments

# Tox & Drug Product Lookup



Monograph search  Keyword search

Feedback Mobile access User account Logout

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax® / Pediatrics	<b>Tox &amp; Drug Product Lookup</b>	RED BOOK	Calculators	Formulary
------	-------------------	------------------	---------	-----------------	-----------	----------------------	--------------------------------------	----------	-------------	-----------

## Tox 和藥物產品查找

Products and Substances

Martindale Global Drug

Company Contacts

Name or Code  Search for product or substance

查找名稱或代碼

### Search by Name

- Drug product name
- Commercial/household product name or chemical
- Substance including plant and animal scientific or common name
- Slang terms/street names for drugs or substances

### Search by Code

- AAPCC code - [Lookup Definitions](#)
- Micromedex product ID
- National Drug Code (NDC)
- Chemical Abstracts Service (CAS) number
- Drug Identification Number (DIN - Canada)
- Environmental Protection Agency (EPA) code
- Universal Product Code (UPC)
- Pest Control Product (PCP) code
- California Registry Number (CRN)
- Fertilizer Act

Products and Substances

Martindale Global Drug

Company Contacts

Ingredient  Search for one ingredient

查找成分名稱

### Search by Ingredient

Find all generic entries, drug products, and commercial products by:

- Active ingredient
- Excipient

# Tox & Drug Product Lookup



Monograph search

Feedback Mobile access User account Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## Tox 和藥物產品查找

Products and Substances

Martindale Global Drug

Company Contacts

Name or Code

**Acetone**

- Acetone - Item No. 13-260
- Acetone - Item No. 13-261
- Acetone - Item No. 13-261EXP
- Acetone - Item No. 13-264
- Acetone - Item No. 13-264EXP
- Acetone - Item No. 13-268
- Acetone - Product Code 23-269
- Acetone - Product Code 83-261
- Acetone - Product Code 83-261-6
- Acetone 12272
- Acetone 14429
- Acetone 1640

輸入查找的藥物名稱後，在符合條件的建議選單中直接點擊藥物

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

TOX 藥物性副作用

  X

United States [Other Countries](#)

選擇左側的藥物，右側會對應產生細項連結資訊

View page: [Preview](#) [List](#)

名稱	Active Ingredient	Physical Description	Company	AAPCC
8. Acetone	acetone	Clear Liquid	Opi	104341
9. Acetone	Acetone	Clear Liquid	Sigma-Aldrich	104260
10. Acetone	Acetone - 99 to 100%	Clear Liquid Colorless	Univar USA	104260
11. Acetone	Acetone - 99 to 100%	Clear Volatile Liquid Colorless	Univar USA	104260
12. Acetone	Acetone - Greater Than 95%	Liquid	Aerchem	104260
13. Acetone	Acetone - Less Than or Equal to 100%	Liquid Colorless	Ashland	104260
14. Acetone	Acetone - 99% Weight %	Liquid	Fisher Scientific	104260
15. Acetone	Acetone	Liquid Colorless	Flinn Scientific	104260
16. Acetone	Acetone - Less Than or Equal to 100%	Liquid Colorless	Nexeo Solutions	104260

[Print](#)

### Acetone

**Micromedex Product ID**  
2394916 - 11/75

**AAPCC**  
104260 - Acetone (Excluding Nail Polish Removers)

#### Toxicology Documentation

**POISINDEX 管理**

- [Acetone](#)

**MEDITEXT 醫療管理**

- [Acetone](#)

**HAZARDTEXT Hazard Response Management**

- [Acetone](#)

#### Overview

**Also Known As**

- Aceton
- Dimethylformaldehyde
- Dimethyl ketal

# Tox & Drug Product Lookup



Monograph search

Feedback Mobile access User account Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup**



Paxlovid (Pfizer, Austral.)

**Micromedex Product ID**  
65068-n3788-z

### Martindale Monographs

MARTINDALE - The Complete Drug Reference

- [Nirmatrelvir](#)
- [ritonavir](#)

### 成分

**Active Ingredients**

- Nirmatrelvir
- ritonavir

[Search similar products](#)

**Indications**

- COVID-19 infection

### Overview

<b>Company</b>	<b>Country</b>
Pfizer, Austral. Pfizer P/L	Australia

### Company Contacts

**Company**  
Pfizer, Austral. Pfizer P/L

**Address**  
38-42 Wharf Rd,  
West Ryde,  
NSW 2114,  
Australia



## Tox 和藥物產品查找 查詢 Martindale 英國藥典

Products and Substances

**Martindale Global Drug**

Company Contacts

**Paxlovid**

名稱	Active Ingredient	Company	國家/地區
1. Paxlovid	Nirmatrelvir ritonavir	Pfizer, Austral. Pfizer P/L	Australia
2. Paxlovid	Nirmatrelvir ritonavir	Pfizer, Cz. Pfizer sro	Czech Republic
3. Paxlovid	Nirmatrelvir ritonavir	Pfizer, Denm. Pfizer ApS Danmark	Denmark
4. Paxlovid	Nirmatrelvir ritonavir	Pfizer, Fr. Laboratoires Pfizer	France
5. Paxlovid	Nirmatrelvir ritonavir	Pfizer, Hong Kong Pfizer Corporation Hong Kong Ltd	Hong Kong

# Tox & Drug Product Lookup



Monograph search  Keyword search

Feedback Mobile access User account Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

## Tox 和藥物產品查找

查詢藥廠資訊

Company Contacts

- Products and Substances
- Martindale Global Drug
- Company Contacts

Pfizer

- Pfizer (Agricultural Division)
- Pfizer (Australia)
- Pfizer (Denmark)
- Pfizer (France)
- Pfizer (Germany)
- Pfizer (Great Britain)
- Pfizer (India)
- Pfizer (Ireland)
- Pfizer (Israel)
- Pfizer (Japan)
- Pfizer (Malaysia) Sdn Bhd
- Pfizer (Mexico)

Pfizer.

Company	Address	聯絡資訊
1. <a href="#">Pfizer</a>	8-12 Block B Fifth Square Chaoyangmen North Street Dongcheng District Beijing 100010 China	
2. <a href="#">Pfizer</a>	235 East 42nd Street New York, NY 10017-5755	<div style="display: flex; justify-content: space-between;"> <div>  Phone (800) 223-0182   Business Hours                             </div> <div>  Phone (888) 879-3477   Business Hours                             </div> </div> <p style="text-align: center; color: #00aaff;">Show more (3)</p> <p style="text-align: center; font-size: small;">Company will accept collect calls in an emergency.</p>
3. <a href="#">Pfizer</a>	Avda Europa 20B Epmresarial La Moraleja Alcobendas 28108 Madrid Spain	

# Red Book



Monograph search  Keyword search

Feedback  Mobile access  User account  Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax® / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators
- Formulary

提供查詢藥品代碼、藥價等相關資料

[轉到自訂表單管理器](#)

按照產品名稱或製造商搜尋處方或處方藥、保健品、散裝化學品、醫療設備或用品。按照產品的特定活性成分或按照特定代碼（例如 NDC、UPC 或 HRI）進行搜尋。

我想按以下項搜尋...

- 產品名稱
- 活性成分
- NDC/HRI/UPC
- 製造商名稱

我想按以下項篩選...

- 狀態：
- 作用中
  - 已停用
  - 全部
- 重新包裝商：
- 包括重新包裝商
  - 排除重新包裝商

輸入搜尋詞：

AMANTADINE

AMANTADINE HCL

AMANTADINE HCL AVPAK AMANTADINE HCL

Details	品牌	產品名稱	活性成分	製造商/分類商	Rpk	學名藥	標本	代碼	識別碼	劑型	強度	用法	包裝大小	單位	WAC	AWP	AWP
	變更	變更					代碼	類型						劑量	組合價格	組合價格	單價
			AMANTADINE HCL												\$1.00		

## Calculators

### All Calculators

Alphabetical Order

### By Category

依種類

- Frequent Use Calculators
- Unit and Dose Converters
- Medical Equations
- Clinical Criteria
- Decision Trees

### By Specialty

依專業

- All Specialties
- Pharmacology
- Nursing
- Medical Statistics

### Math Calculator

數學計算

- Math Calculator

### About

- Glossary
- References

### All Calculators

Alphabetical Order

Find a calculator

Or click a letter to jump to that section. Click on a link below to use a formula or criteria.

跳轉到： [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

Displaying 739 calculators

## A

- A-a Gradient
- AaPO<sub>2</sub> Correction for FIO<sub>2</sub>
- ABCD Rule Predicting Stroke Within 7 Days of a TIA
- ABCD<sub>2</sub> Score to Predict Stroke Risk after TIA
- Absolute Eosinophil Count
- Absolute Lymphocyte Count
- Absolute Neutrophil Count
- Absolute Phagocyte Count
- Absolute Reticulocyte Count

# Calculators

## Calculators

### All Calculators

Alphabetical Order

### By Category

**Frequent Use Calculators**

Unit and Dose Converters

Medical Equations

Clinical Criteria

Decision Trees

### By Specialty

All Specialties

Pharmacology

Nursing

Medical Statistics

### Math Calculator

Math Calculator

### About

Glossary

References

### By Category

#### Frequent Use Calculators

#### Antidote Dosing And Nomograms

- Blood Level Concentration Estimates of Various Alcohols
- Acetaminophen (Paracetamol) Toxicity Assessment (Revised 2023) <sup>New!</sup>
- NAC Dosing for Acetaminophen Overdose
- Ethanol - Initial IV Dosing for Methanol/Ethylene Glycol Overdose
- Ethanol - IV Dosing Adjustment for Methanol/Ethylene Glycol Overdose

#### Laboratory Values

- Creatinine Clearance Estimate by Cockcroft-Gault Equation
- Creatinine Clearance Estimate by Cockcroft-Gault Equation (SI units)
- Creatinine Clearance Estimate by Cockcroft-Gault Equation with Ideal Body Weight

#### Dosing Tools

- ACLS: Adult Emergency Drug Dosing Calculator**
- PALS: Pediatric Emergency Drug Dosing Calculator
- Heparin Dosing Calculator
- IV Drip Maintenance Rate Calculator
- Maintenance Fluid Calculation for Children Based on Hourly Fluid Requirements
- Maintenance fluid calculation for children based on daily fluid requirements
- Carboplatin AUC Dosing in Adults (Calvert formula)
- Benzodiazepine Dosing Conversions
- Adult Vancomycin AUC Continuous Infusion Dosing Adjustment <sup>New!</sup>
- Adult Vancomycin AUC Continuous Infusion Initial Dosing <sup>New!</sup>
- Adult Vancomycin AUC Intermittent Infusion Dosing Adjustment <sup>New!</sup>
- Adult Vancomycin AUC Intermittent Infusion Initial

#### Clinical Calculators

- A-a Gradient
- Calcium Correction in Hypoalbuminemia
- Anion Gap
- Morphine Milligram Equivalent (MME) Dosing Estimate

#### Measurement Calculators

- Body Mass Index (BMI) Quetelet's index
- Body Surface Area (BSA Du Bois Method)
- Body Surface Area (BSA, Mosteller, square root method)
- Ideal body weight (method of Devine) and adjusted body weight for adults
- SI Unit Conversions: Drugs
- Ideal Body Weight
- Ideal Body Weight (method of Devine) and adjusted body weight for adults

# Calculators

Merative **Micromedex**<sup>®</sup>

< All Calculators

## ACLS: Adult Emergency Drug Dosing Calculator

**Input**

Patient Name: Patient

Weight\*: 80 kg

gm  
kg  
lb

Create Dosing Table

輸入體重

輸入病患姓名

輸入病患姓名

### Notes

- Use this calculator to generate a weight based dosing sheet for commonly used emergency medications.
- **Weight\*** is a mandatory input.
- You must have *pop-ups* enabled to see and print the customized dosing sheet.
- Once you have entered the patient **Weight**, and any optional information, click the **Create Dosing Table** button and the customized sheet will appear in a new window. A print prompt will appear automatically.

### ACLS: Adult Emergency Drug Dosing Calculator

# 80 kg

Date: 2025/10/20 上午10:51:49

Patient Name: Patient

### Recommendations according to AHA guidelines ACLS resuscitation.

\*Attention - Institutionally dispensed drug concentrations may vary.

Drug	Concentration	Route	Dose
<b>Adenosine</b>			
6 mg	3 mg/mL	Rapid IV Push	6 mg (2 mL) over 1 to 3 seconds
May Repeat: 12 mg X 2 MAX: 30 mg	3 mg/mL	Rapid IV Push	May Repeat: after 1 to 2 minutes, 12 mg (4 mL) over 1 to 3 seconds; may repeat another 12 mg after 1 to 2 minutes  MAX: 30 mg
Follow adenosine IV push with 20 mL saline flush. Higher doses may be required in patients taking theophylline.			
<b>Amiodarone: Cardiac Arrest</b>			

## 客製化的ACLS清單

150 mg	1.5 mg/mL	Slow IV Push	150 mg (10 mL/min) over 10 minutes
May Repeat: 150 mg	1.5 mg/mL	Slow IV Push	May Repeat: 150 mg
Mix 3 mL from a 50 mg/mL vial in 100 mL D5W for a 1.5 mg/mL solution.			
1 mg/min	1.8 mg/mL	Infusion	1 mg/min (33 mL/hr) for 6 hours, then 0.5 mg/min (16 mL/hr)
MAX Cumulative Dose: 2.2 g over 24 hours			MAX Cumulative Dose: 2.2 g over 24 hours
Mix 18 mL of 50 mg/mL vial in 500 mL D5W for a 1.8 mg/mL solution.			
<b>Atropine sulfate: Bradycardia</b>			
1 mg	0.1 mg/mL	IV Push	1 mg (10 mL)
May Repeat: 1 mg	0.1 mg/mL	IV Push	May Repeat: 1 mg every 3 to 5 minutes
MAX Cumulative Dose: 3 mg			
If manufacturer recommendation is unknown then use maximum available.			
<b>Diltiazem</b>			
15 to 20 mg	5 mg/mL	IV	Initial Dose: 20 mg (4 mL) over 2 minutes (min)
May Repeat: 20 to 25 mg after 15 minutes			May repeat after 15 min: 25 mg (5 mL)
5 to 15 mg/hr	1 mg/mL	Infusion	Starting Rate: 10 mg/hr (10 mL/hr)
Mix 25 mL from a 5 mg/mL vial in 100 mL D5W for a 1 mg/mL solution. Titrate infusion to atrial fibrillation heart rate.			
<b>DOBUTamine hydrochloride</b>			
5 to 10 mcg/kg/min	1000 mcg/mL	Infusion	Starting Rate: 400 mcg/min (24 mL/hr)
			Dose based on 5 mcg/kg/min
Mix 20 mL of a 10 mg/mL vial in 200 mL of D5W for a 1000 mcg/mL solution.			



# Q & A Thank You!

客戶服務中心

服務專線：02-7731-5800

服務傳真：02-8226-5022

客戶服務信箱：[services@customer-support.com.tw](mailto:services@customer-support.com.tw)

專人服務時間：週一～週五 09:00~12:00、13:30~17:30

系統服務時間：全年無休